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Summary 
Glucokinase (GK) also known as hexokinase IV catalyzes phosphorylation of glucose to 
glucose-6-phosphate. In contrast to other hexokinases, GK has a low affinity for glucose, is not 
inhibited by its reaction product and, although existing as monomer, displays sigmoidal kinetics. 
Defects in the GK gene lead to maturity-onset diabetes of the young type 2 (non-insulin-
dependent [MODY-2]). Thus, GK plays an important role for maintenance of glucose 
homeostasis. GK is predominantly expressed in hepatocytes of the liver, pancreatic β-cells and 
some neuroendocrine cells of the gastrointestinal tract and the brain. Insulin and glucagon are 
the major hormones regulating expression of GK in hepatocytes. Thereby, insulin acts mainly via 
the PI3K/PKB pathway and modulates the activity of several transcription factors such as sterol 
regulatory element binding protein-1 (SREBP-1) and FoxO/forkhead transcription factors (FoxO). 
Recent reports from cell culture experiments and transgenic mice indicated that both SREBP-1 
and FoxO1 may act in an antagonistic fashion on GK expression and thus on hepatic 
glucose/lipid metabolism. However, the complete details of the SREBP-1 and FoxO1 regulated 
GK gene expression are not yet known.  
Therefore, it was the aim of this study to investigate, the insulin-dependent SREBP-1- and 
FoxO1-mediated GK gene expression at the molecular level in primary rat hepatocytes and 
HepG2 hepatoma cells. Stimulation of primary hepatocytes with insulin induced GK and SREBP-
1 expression. Similarly SREBP could be induced by treatment with the LXR agonist TO901317 
which in turn induced GK mRNA levels. Likewise, overexpression of SREBP-1 in hepatocytes 
induced GK mRNA levels. Computer analysis of the liver-specific GK promoter revealed three 
putative SREBP-1 binding sites (SREs). Transfection experiments in hepatocytes and HepG2 
cells with luciferase gene constructs driven by serially deleted GK promoter fragments indicated 
that a sequence known as the footprint B site is critically involved in SREBP-1-dependent 
regulation. Further analysis of the footprint B site which could be divided in part 1 and part 2 
showed that part 2 rather than part 1 is necessary for the SREBP-1 effect. In addition, two other 
sequences termed SRE2 and SRE3 were identified by mutation analyses of GK promoter. 
Interestingly, transfection data in primary hepatocytes and HepG2 cells implicated that these 
elements are utilized in a cell-specific manner. While both SRE2 and SRE3 are important for the 
SREBP-1-mediated GK promoter activity in primary hepatocytes, only SRE2 contributed to the 
SREBP-1 effect in HepG2 cells. Moreover, the SREBP-1-mediated activation of the GK 
promoter was lost upon mutation of the HNF-4 binding element indicating that full induction of 
GK gene expression by SREBP-1 requires interaction of these transcription factors. 
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Insulin has a dynamic effect on FoxO transcription factors which are mediated by PKB-
dependent phosphorylation which lead to inactive FoxO by nuclear exclusion. Hepatocytes 
transfected with FoxO1 expression vectors down regulated GK mRNA and GK promoter activity 
and the repression was lost when hepatocytes were stimulated with insulin. When rats were 
fasted for 48 h the GK protein levels were nearly undetectable, whereas FoxO1 protein levels 
were induced. In addition to insulin, transcriptional activity of FoxO proteins is known to be 
regulated by NAD+-dependent SIRT1 deacetylases. Resveratrol down regulated GK mRNA and 
protein levels and reversed the inducing effects of insulin. Similar results were observed with the 
GK enzyme activity. Computational analysis of the GK promoter predicted two FoxO1 binding 
elements (FBEa and FBEb). Overexpression of FoxO1 suppressed GK promoter activity in 
primary hepatocytes and HepG2 cells. Mutations in the FoxO1 binding element FBEb abolished 
the FoxO1-mediated repression of GK promoter. Further, treatment of hepatocytes with the 
SIRT1 activator resveratrol deacetylated and activated FoxO1. Resveratrol also down regulated 
GK promoter activity in transfected hepatocytes; it was unable to repress promoter activity when 
FBEb was mutated. Interestingly, the FoxO1 effect was also lost when the HNF-4 binding site 
was mutated. This suggested that FoxO1 interacts physically with HNF-4 to mediate its action. 
Indeed, coimmunoprecipitation assays revealed that FoxO1 physically interacts with HNF-4.  
Together, the present study showed that SREBP-1 could activate GK gene expression via the 
footprint B2 site, SRE2 and interaction with HNF-4. Although interaction with HNF-4 is also 
important for the FoxO1-dependent GK promoter regulation, two additional binding sites were 
identified. The FoxO1 activity was shown for the first time to be regulated by resveratrol and 
SIRT1, and the resveratrol-mediated down regulation of GK expression was due to either 
binding of FoxO1 to the binding elements or via interaction with HNF-4.  





In mammals glucose can be utilized by all cells to produce ATP and additionally in hepatocytes, 
myocytes and cardiomyocytes to form glycogen which serves as an energy store. Glucose 
enters into the cells through glucose transporters (GLUT) from which at least 5 have been 
identified. The first step of glucose utilization is phosphorylation of glucose to glucose-6-
phosphate. This can be done by four different hexokinases I-IV from which hexokinases I-III 
have relatively high affinities for different hexose substrates and their molecular mass is about 
100 kDa. The hexokinases I-III are inhibited by physiological concentrations of their reaction 
product glucose-6-phosphate (G6-P). In contrast, hexokinase IV (EC 2.7.1.2), also known as 
glucokinase (GK) with a mass of about 52 kDa exhibits and displays sigmoidal kinetics with a Hill 
coefficient of ~ 1.5 – 1.7 and is not inhibited by its reaction product glucose 6-phosphate. Even 
though glucose is the preferred substrate of the enzyme, GK can also convert mannose to 2- 
deoxyglucose and fructose (Lenzen et al., 1987). However, GK is inhibited by glucosamine and 
its derivatives, by mannoheptulose, alloxan, and in vitro by palmitoyl-CoA and other long chain 
acyl-CoA esters. 
 
1.1.1 Glucose homeostasis 
GK was first discovered in the liver (Grossbard and Schimke, 1966) and a few years later GK 
activity was also assigned to pancreatic cells (Matschinsky et al., 1968). Later it was shown that 
GK expression is not only restricted to hepatocytes and pancreatic β-cells, but is also present in 
some neuroendocrine cells of the gastrointestinal tract and the brain (Jetton et al., 1994). The 
hepatic GK exerts a very strong influence on glucose homeostasis by glucose utilization and 
glycogen synthesis. Small variations of GK levels in transgenic mice modulated blood glucose 
concentration (Hariharan et al., 1997). In addition, overexpression of GK in primary hepatocytes 
led to elevations in glucose 6-phosphate (O'Doherty et al., 1996), which as a central metabolite 
triggers increased rates of glycolysis and glycogen synthesis (Aiston et al., 1999). The 
importance of GK was underlined by the findings that homozygous knockout mice died a few 
days after birth and heterozygous knockout mice appeared normal at birth but died within 4 days 
due to a defect in insulin secretion in response to glucose and hyperglycaemia (Bali et al., 
1995). In addition, β-cell-specific knockout mice were similar to global GK knockout mice 
showing hepatic steatosis, a depleted hepatic glycogen content and an ~70% decrease in 
plasma insulin concentrations suggesting the role of GK as glucose sensor in β-cells. In 
contrast, liver specific loss of hepatic GK was not lethal and had relatively small effects on 
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plasma glucose concentration. These results indicate a cooperative mode of both β-cell GK and 
hepatocyte GK in the regulation of glucose homeostasis.    
In pancreatic β-cells, GK was considered to be the ‘glucose sensor’ (Garfinkel et al., 1984), as 
the phosphorylation of glucose within β-cells is tightly coupled to insulin secretion. When glucose 
enters the β-cell by type 2 glucose transporters it is phosphorylated by GK and converted to 
glucose-6-phosphate, which effectively traps glucose inside the cell. As glucose metabolism 
proceeds, ATP is produced in the mitochondria. This increase in the ATP:ADP ratio shuts ATP-
gated potassium channels in the β-cell membrane, thus keeping  positively charged potassium 
ions inside the β-cell. This decrease in K+-efflux depolarizes the β-cell, resulting in opening of 
voltage-gated calcium-channels, which in turn flood Ca2+ ions into the β-cell. The increase in 
Ca2+ ion concentration then triggers the secretion of insulin via exocytosis (Gilon et al., 2002). 
Thus, even small changes in GK activity can be physiologically significant, as they directly affect 





Figure 1. Role of glucokinase in glucose 
homeostasis and the interplay between 
pancreatic β-cells and hepatocytes In 
pancreatic β-cells, glucose is transported into 
the cells via glucose transporter Glut2, and 
phosphorylated by GK to yield glucose-6-
phosphate (G6-P). Subsequently, glycolysis 
and mitochondrial metabolism increase the 
ATP:ADP ratio, thus leading to inactivation of 
the Kir6.2 potassium channel, and following a 
depolarisation of the membrane, to an influx 
of Ca
2+
 which triggers insulin secretion. 
Glucose per se or a glucose metabolite, such 
as G6-P, can activate GK expression either 
transcriptionally, translationally or post-
translationally. Insulin can also activate GK 
expression via a transcriptional mechanism. 
In hepatocytes, insulin acts as the primary 
activator of GK transcription, the prerequisite 
for production of G6-P by GK and the storage 
of glucose as glycogen, which is stimulated 
by insulin. Conversion of glucose to G6-P 
with subsequent glycolysis also leads to 
acetyl-CoA formation which can be used for 
lipid synthesis. 
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1.1.2 Glucokinase regulatory protein (GKRP) 
In the liver, GK activity and subcellular localization is regulated by a 68 kDa GK regulatory 
protein (GKRP) in conjugation with fructose 6-phosphate (F6-P) (Vandercammen and Van, 
1990). GKRP inhibits GK, with respect to glucose, by forming a protein-protein complex which is 
sequestered in the nucleus. This effect can be reversed by high glucose or fructose 1-phosphate 
(F1-P) (Veiga-da-Cunha and van Schaftingen, 2002). Surprisingly, GK lacks a nuclear 
localization sequence and entry into the nucleus depends on GKRP by a piggy-back 
mechanism. By contrast, GK has a nuclear export signal (NES) sequence (300 ELVRLVLLKLV 
310) near to its carboxy terminus that is masked upon binding of GKRP, thus ensuring that the 
GK-GKRP complex remains in the nucleus (Shiota et al., 1999). When blood glucose levels rise 
after feeding, GKRP is released from GK and allows export from the nucleus to the cytoplasm 
via an active process. Within the cytoplasm GK is catalytically active and converts glucose to 
glucose 6-phosphate. However, as the blood glucose levels begin to fall, GKRP binds 
cytoplasmic GK and moves it back into the nucleus.  
GKRP ‘knockout’ experiments showed that homozygous GKRP-/- mice have a ~ 40% reduction 
in liver GK protein levels and enzymatic activity. These deficient mice show an impaired glucose 
tolerance to a bolus of injected glucose, which is due to the inability to recruit GK from a nuclear 
reserve. These results strongly suggest the physiological role of the regulatory protein which 
may aid to provide a functional reserve of GK that can be quickly released after a meal. 
However, it is questioned whether GKRP as such is present in the pancreatic β-cell. 
Alternatively, although splice variants of GKRP have been described, it appears that other GK-
binding partners exist, including long chain fatty acyl-CoA, propionyl-CoA carboxylase β-subunit 
precursor, insulin-containing granules and nitric oxide synthase (NOS), dual specific 
phosphatase (DUSP12), the bifunctional enzyme 6-phosphofructo-2-kinase/fructose-2-6-
bisphosphatase (PFK-2/FBPase-2) and β-cell matrix proteins (Baltrusch et al., 2001). 
 
1.1.3 Glucokinase protein structure 
The resolved GK crystal structure allowed an easier elucidation of its unique kinetic properties. 
The crystal structure of GK unveiled a palm shaped structure with a small and large domain 
separated by an interdomain cleft. The connecting region, Asn204 and Asp205, in conjunction 
with Glu256 and Glu290 of the large domain and Thr168 along with Lys169 of the small domain, 
are involved in glucose binding. In addition, an allosteric site was identified at the interface 
between the two domains and is surrounded by connecting region-I, the large domain (β1strand 
and α5 helix) and the small domain (α13 helix) (Kamata et al., 2004). 
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The GK can be found in two confirmations along with an intermediate confirmation. Without 
glucose, GK exists in its thermodynamically favorable wide-open inactive confirmation. Once 
bound to glucose, GK undergoes a conformational change and switches from the inactive wide-
open to an intermediate active open confirmation and then to the very active closed form. Upon 
conversion of glucose, G6-P and ADP will be released and GK returns via the open confirmation 
to the wide-open form. As both forms slowly equilibrate and the conformational change from the 
closed to the open form is faster than from wide-open to open and vice versa, it appears that a 
large portion of GK exists in the open form for some time (Fig 2). These conformational changes 
indicate that GK operates in two cycles: a fast cycle and a slow cycle. If glucose binds to the 
intermediate open form, GK immediately enters into the catalytic cycle; if not (e.g., low glucose 
concentration) GK returns to the wide-open form and uses the slow cycle. This shift between 
catalytic cycles explains the mnemonic mechanism and the sigmoidal saturation curve for 




Figure 2. Model of the two glucokinase reaction cycles 
The glucose-unbound glucokinase (GK) exists in a wide-open confirmation. When glucose binds to it, GK 
undergoes confirmational changes from the wide-open to the close active confirmation via the 
intermediate open but active conformation. After conversion of glucose, GK returns to the open form, 
thereby releasing glucose 6-phosphate (G6-P) and ADP. At this stage, the enzyme may aquire a new 
glucose molecule and may undergo an immediate new reaction (fast cycle) or, as under low glucose 
concentrations, return to the wide-open inactive conformation.  
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1.1.4 Glucokinase gene  
Glucokinase is encoded by a single gene in humans, rats and mice. The human GK gene is 
located on chromosome 7p13, whereas the mouse gene is located on chromosome 11. The 
gene consists of 10 exons and has two widely separated and functionally distinct cell-type-
specific promoters. Cloning and characterization of an 83 kb clone (P1-305) having both 
promoters and all coding sequences of the mouse GK revealed that the 11 exons of total gene 
span 49 kb, with exons 1β (upstream promoter) and 1L (downstream promoter) being separated 
by ~35 kb (Postic et al., 1995). These alternate promoters in conjunction with the use of different 
first exons lead to tissue-specific GK expression. The β-cell GK mRNA is a product of exon 1a 
and 2-10, whereas the liver expresses GK from exons 1b and 2-10 and 1b, 1c and 2-10 due to 
alternate splicing. 
The upstream (β-cell promoter) GK promoter is expressed specifically in several different cell 
types including pancreatic β-cells, neural/neuroendocrine cells of the gastrointestinal tract and 
corticotropes of the pituitary (Liang et al., 1991). However, the downstream GK promoter is 
mainly responsible for hepatic GK gene transcription. The upstream β-cell specific promoter has 
70% sequence similarity among human, rat and mouse species. 
 
1.1.5 Glucokinase promoter regulation 
DNaseI hypersensitive analysis and DNaseI footprint assays of the liver specific GK promoter 
revealed that, both in rats and mice, the hepatic GK promoter encompasses ~7 kb of 5’ –flanking 
sequence (Postic et al., 1995). DNaseI footprinting assays identified seven elements A – G (in 3’ 
to 5’ direction), specifically interacting with liver enriched factors (Iynedjian et al., 1996). Recent 
studies have identified two binding sites for hepatocyte nuclear factor-6 (HNF-6, the prototype of 
the ONECUT family of transcription factors), located at the most distal (-7613/-7622) and the 
more proximal (-877/-868) sites of the promoter (Lannoy et al., 2002). Further, analysis of the 
more proximal part of the liver specific promoter showed the existence of additional footprints 
named as P2 (-87/-80) and P1 (-54/-35) (Iynedjian, 1998a). The element P2 has been shown to 
be bound by the basic helix-loop-helix transcription factors, upstream stimulatory factor-1 and -2 
(USF-1, -2) (Iynedjian, 1998b), as well as by hypoxia-inducible factor-1 (HIF-1) (Roth et al., 
2004b). The P1 element was identified to contain a binding site for hepatocyte nuclear factor-4α 
(HNF-4 α) (Roth et al., 2002). 
The liver tissue exhibits a metabolic zonation and a zonated gene expression. The zonated 
pattern may be the result of the gradients in nutrients, hormones and oxygen which are formed 
due to the blood flow through the sinusoids and the metabolism of the cells. Especially oxygen 
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or insulin mainly contributes to the zonated gene expression in liver. The liver GK gene 
expression is mainly stimulated by insulin in the hypoxic perivenous zone of the liver (Iynedjian 
et al., 1989), (Krones et al., 2000), involving HIF-1 and HNF-4 to play an important role during 
this process. Previous results have shown that the cooperation between HIF-1, HNF-4 and the 
co-activator p300 contributed to the insulin-dependent GK induction (Roth et al., 2004a). The 
insulin signalling pathway involved in the GK gene expression was the PI3K/protein kinase B 
pathway, which also regulates the insulin-dependent expression of several other genes required 
for carbohydrate metabolism such as glucose 6-phosphatase (G-6-Pase), glucose transporter-1 
(GLUT-1) and sterol regulatory element binding protein-1 (SREBP-1) (Iynedjian PB et al., 2000). 
Very recent reports implicated sterol regulatory element binding protein (SREBP) as an insulin-
dependent activator for transcription of hepatic GK. It has been shown that GK promoter activity 
was induced by SREBP-1a, and found that SREBP-1c binds to two sterol response elements 
designated (SREa -205/-197) and (SREb -183/-174) (Kim et al., 2004). However, the mutual 
relationship between the SREa and SREb is not well understood in the SREBP-1c-mediated 
activation of liver GK by insulin.     
Furthermore, FoxO transcription factors are important targets of insulin signaling and contribute 
to the regulation of cell growth, differentiation, and metabolism. Insulin has a dynamic effect on 
the localization of FoxO. PKB/Akt pathway of insulin signaling inactivates the transactivation and 
promotes nuclear exclusion of FoxO. FoxO proteins exert both positive and negative effects on 
gene expression. Studies with adenoviral vectors in isolated hepatocytes reveal that FoxO1 
stimulates gluconeogenic genes (PEPCK) and suppress glycolytic genes including glucokinase 
and SREBP-1c (Zhang et al., 2006). However, FoxO1-mediated repression of glucokinase gene 
was not understood completely.   
 
1.2 Sterol regulatory element binding proteins (SREBPs)  
SREBPs are membrane bound transcription factors, involved in cholesterol metabolism. 
SREBPs are basic helix-loop-helix leucine-zipper (bHLH-zip) transcription factors, which are 
different from other bHLH-zip proteins in that they are able to bind the typical E-box inverted 
DNA repeat (5’-CANNTG-3’) as well as the direct DNA repeat of SRE (5’-TCANCCAC-3’) 
(Parraga et al., 1998). So far, three SREBP isoforms have been identified and characterized in 
mammalian cells. They are designated as SREBP-1a, SREBP-1c and SREBP-2. SREBP-1a and 
-1c are derived from a single gene located on human chromosome 17p11.2 through the use of 
alternative transcription start sites that produce different forms of exon 1. By contrast SREBP-2 
is derived from a second gene located on human chromosome 22q13.  SREBP-1a is a potent 
transcriptional activator having a long transactivation domain, but SREBP-1c is a much weaker 
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activator since it lacks N terminal 29 acidic amino acids present in SREBP-1a. In vivo studies 
suggested that SREBP-1 proteins are potentially activating lipogenic genes whereas SREBP-2 
activates predominantly genes necessary for cholesterol homoeostasis.  
SREBPs are endoplasmic reticulum membrane-bound transcription factors (Fig 3). Insulin 
induces SREBP transcription via a PI3-kinase pathway (Iynedjian et al., 2000); proteolytic 
cleavage and release of active SREBP may or may not be dependent on insulin. However, 
nanoelectrospray mass spectrometry and peptide sequencing studies have identified that, serine 
117 in SREBP-1 may be a major phosphorylation site of the MAP kinases ERK 1/2 (Kotzka et 
al., 2004). The SREBPs and SREBP cleavage activating protein (SCAP) form a complex that is 
stable in both the presence and the absence of sterols. The amino terminus of SCAP consists of 
a sterol sensing domain and when the cellular sterol levels are low SCAP escorts SREBP from 
the ER to the Golgi apparatus, where the site-1 serine protease (S1P) and the site-2 metallo 
protease (S2P) cleave and release transcriptionally active SREBP. The released SREBPs are 
translocated into the nucleus and bind to its target gene promoters containing SRE or E-boxes 
(Fig 3). 
 
Figure 3. Insulin signalling and SREBP activation pathways When the cellular sterol levels are normal 
sterol regulatory element binding protein (SREBP) forms a complex with SREBP cleavage activating 
protein (SCAP) in the endoplasmic reticulum (ER). When sterol levels decrease, SCAP escorts SREBP to 
the golgi apparatus where site 1 protease (S1P) and site 2 protease (S2P) cleave and release active 
SREBP. The active SREBP migrates into the nucleus and activates transcription of genes such as 
glucokinase or those involved in cholesterol and fatty acid synthesis by binding to sterol response 
elements (SRE) or E-boxes. Insulin, through activation of the phosphatidylinositol 3-kinase pathway, 
increases SREBP-1 expression and thus the amount of SREBP-1. In addition, SREBPs may be regulated 
via phosphorylation since they appear to be a direct substrate of ERK1/2.  
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1.3 FoxO transcription factors 
The forkhead proteins belong to the FOX superfamily of proteins consisting of more than four 
hundred transcription factors. Each factor is characterized by a conserved DNA binding domain 
of 110 amino acids referred as forkhead box or winged helix domain. The forkhead box ‘Other’ 
(FoxO) proteins constitute a class of the FOX protein family, which includes FOXO1 (FKHR), 
FOXO3a (FKHRL1), FOXO4 (AFX) and FOXO6. The FOXO proteins are the vertebrate 
orthologs of the Caenorhabditis elegans DAF16 protein and they are components of a highly 
conserved signaling pathway, which connects growth and stress signals to transcriptional 
regulation (Ogg et al., 1997). The FoxO proteins have an important role in mediating the effects 
of insulin and growth factors on diverse physiological functions, comprising cell proliferation, 
apoptosis and metabolism. Early studies on the regulation of insulin-like growth factor binding 
protein-1 (IGFBP-1), provided an important evidence that FoxO proteins interact with insulin 
responsive sequences [IREs-(T/C)(G/A)AAACAA] and are regulated through the 
phosphatidylinositol 3-kinase and protein kinase B pathway (Unterman et al., 1994).  
Transcriptional activity of the FoxO proteins requires nuclear localization, which is favored by the 
absence of growth signals. In response to insulin or growth signals, FoxO factors are 
phosphorylated by several kinases including protein kinase B, serum and glucocorticoid-
regulated kinase (SGK), casein kinase1 (CK1), and DYRK1A (a member of the dual-specificity 
tyrosine-phosphorylated and regulated kinase group) {(Arden and Biggs, III, 2002), (Brunet et 
al., 2001), (Guo et al., 1999)}. Phosphorylation of FoxO factors by PKB/Akt occurs at three 
conserved residues namely N-terminal Thr24, Forkhead domain Ser256, and C-terminal Ser319, 
which results in disrupting the interaction with the other transcriptional coactivators, affecting the 
DNA-binding activity, and masking the nuclear localization signal. This facilitates the binding of 
14-3-3 proteins leading to nuclear exclusion of FoxO (Fig 4). 
FoxO transcription factors are acetylated at conserved lysine residues located in the DNA-
binding domain (Fukuoka et al., 2003) by p300 and co-activators displaying histone 
acetyltransferase activity. This leads to attenuation of FoxO as a transcription factor. Conversely, 
SIRT1 a member of the Sir2 family of NAD-dependent deacetylases (Brunet et al., 2004) binds 
to and deacetylates FoxO (Fig 4). This interaction with SIRT1 affects the transcriptional 
regulatory functions of FoxO and is depending upon the FoxO target genes. The rate of 
deacetylation activity of SIRT1 has been shown to be doubled by treating with a compound 
called resveratrol. Resveratrol is a polyphenol found in Polygonum capsidatum, including 
mulberries, pea nuts and grapevines. It has a broad range of biological effects besides 
deacetalytion, including chemopreventive properties against several cancers, cardiovascular 
diseases, viral infections, diabetes and protection of cells from lipid accumulation. 
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Pharmacokinetic and pharmacodynamic studies demonstrated that the main target organs of 
resveratrol are liver and kidney (Shankar et al., 2007).      
 
 
Figure 4. Activation and inactivation of FoxO mediated gene expression FoxO transcription factors 
are predominantly nuclear and are presumed to be active. Insulin via PKB mediates phosphorylation of 
FoxOs on three conserved residues in the nucleus, which initiates their export to the cytoplasm. This 
would lead to the repression of gene expression. Activation of FoxO by glucagon via cAMP leads to 
nuclear import and induction of target genes. Treatment with resveratrol increases NAD+-dependent 
SIRT1 deacetylases, which are known to interact and deacetylate cytoplasmic inactive acetylated FoxOs 
into active. Thus deacetylated FoxOs may be imported into the nucleus and act on target genes.  
Insulin receptor substrates (IRS); phosphoinositide 3-kinase (PI3K); protein kinase B (PKB); 
phosphatidylinositol 3,4,5-triphosphate (PI[3,4,5]P3); pyrophosphatase (PPase); cyclic adenosine 
monophosphate (cAMP); Silent information regulator 1 (SIRT1).  
 
1.4 Hepatocyte nuclear factor 4 (HNF4α) 
HNF4α is a member of the nuclear hormone receptor family of transcription factors consisting of 
two zinc fingers in the DNA binding domain. The gene encoding HNF4α is located on 
chromosome 20 and is expressed in the liver, kidney, pancreas, small intestine, testis and colon. 
HNF4α knockout mice are embryonic lethal due to a failure in gastrulation and the expression of 
many genes involved in liver development (Li et al., 2000). Besides organ development, HNF4α 
has an important role in glucose and lipid homeostasis (Ladias et al., 1992). Mutations in the 
HNF4α gene cause maturity-onset diabetes of the young type-1 (MODY-1). HNF4α regulates 
genes at the transcriptional level by interacting with the HNF4 binding elements on the promoter 
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or enhancer (Bogan et al., 2000). The HNF4α protein contains several functional domains: a 
ligand-independent activation domain (AF1), a zinc finger DNA binding domain, and a ligand-
dependent activation domain (AF2). Crystal structure studies of the ligand binding domain had 
identified fatty acids or related molecules might act as endogenous ligands for HNF4α (Dhe-
Paganon et al., 2002).   
 
1.5 Aim of the study 
Glucokinase is predominantly expressed in the perivenous zone of the liver acinus where the 
concentration of insulin is high due to metabolic zonation. Insulin regulates several transcription 
factors including hypoxia-inducible factor-1α (HIF-1α), forkhead transcription factors (FoxO), and 
sterol regulatory element binding proteins (SREBP). It is well known that, the transcription 
factors SREBP and HNF4α activate the GK promoter. However, the molecular mechanisms 
underlying the regulation of GK gene by SREBP and HNF4α are poorly understood. Therefore, 
the purpose of the current study was to investigate the insulin-dependent SREBP mediated 
glucokinase gene expression and to map the SREBP responsive elements within the liver-
specific GK promoter. Insulin has dynamic effects on FoxO transcription factors and these 
factors are transcriptionally active when insulin signaling is absent. FoxO factors are known to 
be positive regulators of gluconeogenic genes and negative regulators of glycolytic genes. The 
effects of FoxO factors on glucokinase gene expression are not well known. Therefore, we 
intended to investigate the regulation of glucokinase gene by FoxO factors and to identify 
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2. Materials 
2.1 Animals 
Male Wistar rats (~200-300 g) were housed in controlled environmental conditions of 12 h light 
/12 h dark cycle (light from 07.00 to 19.00 h) according to the German legislation on the 
protection of animals. Rats were fed ad libitum with laboratory diet (Altromin breed fodder) and 
free access to water. The rats consumed 12-15 g food and 12-25 ml water per day and had a 
30-40 g gain of weight per week. Rats were anaesthetized with pentobarbital (60mg/kg body 
weight) prior to the preparation of hepatocytes between 09.00 and 10.00 h. 
 
2.2 Bacterial strains, vectors and plasmid constructs 
Escherichia coli bacterial strain’s DH5α and XL1 blue (Hanahan, 1983) were used for 
transformation of various plasmids and ligation reactions. 
 
2.2.1 Vectors 
2.2.1.1 pBluescript-KS II vector 
pBluescript-KS II vector is designed for DNA cloning, sequencing, in vitro mutagenesis and in 
vitro transcription in a single system (Stratagene, Heidelberg). The pBluescript KS II is a 
phagemid and is derived from the vector pUC 19 consisting of 2961 bp. This vector consists of 
T3 and T7 RNA polymerase promoters, necessary for the in vitro transcription, a multiple cloning 
site (polylinker) containing sites for different restriction endonucleases, and primer sequences 
(universal) necessary for DNA sequencing (Fig. 5).      
2.2.1.2 pTZ57R/T (T/A cloning vector to clone PCR fragments) 
The vector pTZ57R was pre-cleaved with Eco321, an isoschizomer of EcoR V and treated with 
terminal deoxynucleotidyl transferase to create 3’ –ddT overhangs at both ends to generate 
pTZ57R/T vector (2886 bp). This specially designed cloning vector has high efficiency and 
allows the cloning of Taq-amplified PCR fragments without any post-PCR treatment. The T/A 
cloning method is especially suitable for cloning of PCR fragments amplified with primers that 
carry dG or dC at their 5’-ends (Fig. 6). 
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Figure 5. The vector pBluescript vector (pBS-KS II). The vector contains the origin of replication ColE1 
ori, the ampicillin resistance gene for antibiotic selection, and the LacZ gene coding for β-galactosidase 
which provides the possibility for blue/white colour selection of recombinant clones. The multiple cloning 
site is flanked by T3 and T7 promoters and by the sequences for T3 and T7 primers, KS and SK primers, 
universal (M13) forward and reverse primers for sequencing of DNA fragments inserted into the MCS 
within the lacZ gene. KS and SK represent two orientations of the MCS within the lacZ gene; KS 
represents the orientation of the MCS in which lacZ transcription proceeds from Kpn I to Sac I, while SK –
from Sac I to Kpn I. 
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Figure 6. The pTZ57R/T vector. This is a linear vector consisting of 3’-ddT overhangs on both ends to 
prevent recircularization of vector during ligation. The position of the genetic elements is shown on the 
map. The plasmid consist of f1 (IG) – the intergenic region of phage f1; rep (pMB1) replicon responsible 
for DNA replication and high copy number. The bla gene 2688-2756 codes for ampicillin resistance, the 
lac Z gene encoding the N-terminal fragment of beta-galactosidase which allows blue/white screening of 
recombinant plasmids.   
 
2.2.1.3 pGL3-Basic and pGL3-Promoter vectors 
The pGL3-Basic vector lacks eukaryotic promoter and enhancer sequences, which allows 
maximum flexibility in cloning putative regulatory sequences (mainly promoters). The vector 
contains multiple cloning site (MCS) followed by the firefly luciferase gene (luc+, 1649) and the 
SV40 late polyA signal (221 bp). The plasmid consists of an ampicillin resistance gene (β 
lactamase; Ampr; 857 bp) and two origins of replication, ColE1 ori and f1 ori (454 bp). The 
plasmid also consists of two primer sequences RV3 and GL2, which allows sequencing of the 
cloned fragments. Expression of luciferase activity in cells transfected with this plasmid depends 
on insertion and proper orientation of functional regulatory sequences upstream from luc+.  
Materials   14 
 
Figure 7. Structure of the pGL3-Basic vector. luc+, cDNA encoding the modified firefly luciferase; Ampr, 
gene conferring the ampicillin resistance in E.coli; f1 ori, origin of replication derived from filamentous 
phage; ori, origine of replication in E.coli. Arrows within luc+ and Ampr gene indicate the direction of 
transcription; the arrow in the f1 ori indicates the direction of single-strand DNA synthesis.  
Both pGL3-Basic and pGL3-Promoter vectors are similar except an SV40 promoter upstream of 
the luciferase gene within the pGL3-Promoter vector. DNA fragments containing putative 
enhancer elements can be inserted either upstream of the SV40 promoter luc+ transcriptional 
unit of promoter vector. 
     
Figure 8. Structure of the pGL3-Promoter vector. The multiple cloning site (41 bp) is followed by the 
SV 40 promoter (195 bp), firefly luciferase gene (luc+, 1649 bp) and a SV 40 late polyA signal (221 bp). 
Another, upstream polyA signal (153 bp), is located directly before the multiple cloning site. The plasmid 
also contains the ampicillin resistance gene (857 bp) and two origins of replication, ColE1 ori and f1 ori 
(454 bp). The luc+ gene is transcribed clockwise and the Ampr gene is transcribed counterclockwise.  
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2.2.2 Plasmid constructs 
2.2.2.1 Reporter gene plasmid constructs 
2.2.2.1.1 Glucokinase promoter pGL3-Basic constructs 
The wild type rat glucokinase promoter (1448/+15) along with the deletion constructs  was 
cloned into Bgl II and Hind III restriction sites, in front of the Luc+ gene of the vector pGL3-Basic 
to create the pGL3rGK-1448 Luc, pGL3rGK-919 Luc, pGL3rGK-781 Luc, pGL3rGK-748 Luc, and 
pGL3rGK-333 Luc constructs. The wild type pGL3rGK-1448 Luc construct was used as a 
template to generate different mutation constructs pGL3rGK-mSRE1, pGL3rGK-mSRE2, 
pGL3rGK-mSRE3, pGL3rGK-mSRE2+mSRE3, pGL3rGK-mHNF4, pGL3rGK-mHRE, pGL3rGK-
mHRE+mHNF4, pGL3rGK-mE-box, pGL3rGK-mFPB1, pGL3rGK-mFPB2, pGL3rGK-
dmFPB1+2, pGL3rGK-mFBEa, pGL3rGK-mFBEb, and pGL3rGK-dmFBEab using the 
QuickChange XL site-directed mutagenesis kit (stratagene). 







Figure 9. Rat glucokinase promoter deletion constructs. The wild type rat glucokinase promoter GK-1448 and 
the deletion constructs GK-919 LUC, GK-781 LUC, GK-748 LUC, and GK-333 LUC were cloned into the pGL3-
Basic vector. Black boxes A-G, P1 and P2 indicate foot-printed regions. White boxes indicate elements 
identified only by sequence similarity. Elements P1 and P2 correspond to the binding elements for HNF-4 and 
HIF1. White boxes S1, S2, and S3 are putative SREBP responsive elements (SRE); F1 and F2 are putative 
FoxO binding elements (FBE).   
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Figure 10. Rat glucokinase promoter mutation constructs. The rat wild-type glucokinase promoter 
construct GK-1448 was used as a template to generate all the mutation constructs. Putative SREBP 
responsive elements were mutated alone or in combination to generate GK-1448 mSRE1, mSRE2, 
mSRE3 and a double mutant GK-1448mSRE2+mSRE3. Mutations were incorporated at HNF4 and HIF 
binding sites to create GK-1448mHNF4, GK-1448mHRE and a double mutant GK-1448mHRE+mHNF4. 
The wild-type sequences are shown on the upper strand whereas the mutated sequences are indicated 
down with lower case letters. The numbers above the line indicate the position of the elements. 
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Glucokinase promoter mutation constructs 
 
 
Figure 11. Rat glucokinase promoter mutation constructs. The mutation constructs shown in the 
above diagram were generated from rat wild-type glucokinase promoter construct GK-1448. Mutations 
were incorporated at E-box, foot print B1, B2 and both together to generate GK-1448mE-box, GK-
1448mFPB1, GK-1448mFPB2 and GK-1448dmFPB1+2. Mutations were created in the putative FoxO 
binding elements to generate GK-1448mFBEa, GK-1448mFBEb and both together GK-1448dmFBEab. 
The wild-type sequences are shown on the upper strand whereas the mutated sequences are indicated 
down with lower case letters. The numbers above the line indicate the position of the element.  
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2.2.2.1.2 pGL3-Promoter constructs 
The plasmid construct pGL3-SR/SP-Luc was generated by cloning oligonucleotides carrying the 
sequence for three copies of sterol regulatory element binding elements (SRE) and one SP1 
binding element (SPE) in front of the SV 40 promoter in the pGL3-Promoter vector. Similarly, the 
oligonucleotides consisting of four copies of SREs were cloned in front of the SV 40 promoter in 
the pGL3-Promoter vector to generate the pGL3-4SRE-Luc construct. The oligonucleotides were 
designed in a way to obtain an EcoR I restriction enzyme site between the 3rd and 4th binding 
element. Since this site is not present in the parental vector this will allow the identification of the 




Figure 12. Luciferase gene constructs with oligonucleotides carrying SREBP1 and SP1 responsive 
elements from fatty acid synthase promoter as enhancers. The double stranded oligonucleotides 
carrying the FAS-SRE’s and FAS-SP1 were cloned into the Kpn I and Xho I restriction sites of pGL3-
Promoter vector. The sequences shown in the above figure are the consensus sequence for the binding of 
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Expression plasmid constructs used in this work are listed below. 
Plasmid Description Reference 
pCMV4-SREBP1a460 cDNA coding the 5’-untranslated region and amino 
acids 1-460 of nuclear human SREBP1a under the 
control of the CMV promoter in pcDNA4 vector 
(AMPr, Invitrogen) 
Shimano H et 
al., 1997 
pcDNA3-FLAG FKHR Full length ORF coding for human FKHR tagged with 
FLAG tag under the control of the CMV promoter in 
pcDNA3 (AMPr, Invitrogen) 




human FKHR cDNA with triple mutations at Thr24, 
Ser256, and Ser319 to Ala with FLAG tag under the 
control of the CMV promoter in pcDNA3 (AMPr, 
Invitrogen) 
Tang et al., 
1999 
pCMX HNF4 cDNA encoding the rat HNF4 (NR2A1) under the 
control of the CMV promoter in pCMX vector (Ampr) 




human SIRT1 full length ORF tagged with myc and 
His tags under the control of CMV promoter in 
pcDNA 3.1 (Ampr, Invitrogen) 
Untermann TG 








2.2.2.2 Expression Plasmids  
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2.3 Oligonucleotides 
HPLC purified synthetic oligonucleotides were obtained from MWG (Ebersberg) and 
Operon biotechnologies (Cologne, Germany).   
2.3.1 Primers for sequencing 
Vector    Primer     Sequence 5’          3’                                      
pBS KSII       T7 promoter Primer  5'- TAA TAC GAC TCA CTA TAG GGA GA -3' 
T3 promoter primer  5'- ATT AAC CCT CAC TAA AGG GA -3' 
M13 forward   5´- TGT AAA ACG ACG GCC AG -3´ 
M13 reverse   5´- ACA GCT ATG ACC ATG ATT -3´ 
pTZ57R/T       T7 promoter Primer  5'- TAA TAC GAC TCA CTA TAG GGA GA -3' 
pGL3             RV3 primer (Forward)    5´- CTT TAT GTT TTT GGC GTC TTC C -3´ 
            GL2 primer (Reverse)  5´- CTA GCA AAA TAG GCT GTC CC -3´ 
 
2.3.2 Oligonucleotides for PCR reaction  
Primers used to generate deletion constructs  
Primer name   Sequence 5’          3’ 
GK 1   5’- CTT GGG AGA TCT TGG CAT TCC G -3’ 
GK 2   5’- GTG GCA GAT CTT TTT AGC AGA G -3’ 
GK 3   5’- CAG CAA GAT CTG AGG ATG TTG G -3’ 
GK 4   5’- CTC CGC AGA TCT AAT CCC ACG A -3’ 
9 GK   5’- GTC ATA TGA GAT CTG GTG AGG -3’ 
RGK   5’- GGA ATG CCA AGC TTA AGG AC -3’ 
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2.3.3 Primers used for site directed mutagenesis 
Primer name   Sequence 5’          3’ 
m SRE1 s 5’- CCC ACG AGG AGC CCC CTA TAT TCA CAA GTC TGA AGC C -3’ 
m SRE1 as 5’- GGC TTC AGA CTT GTG AAT ATA GGG GGC TCC TCG TGG G -3’ 
m SRE2 s 5’- CCA GTC TGA AGG GAG GGG ATG GAG TGG GCA GGC -3' 
m SRE2 as 5’- GCC TGC CCA CTC CAT CCC CTC CCT TCA GAC TGG -3' 
m SRE 3 s 5’- GGG CAG GCT CCA GCA TCC TCA TTA ACC TCT CC -3’ 
m SRE 3 as 5’- GGA GAG GTT AAT GAG GAT GCT GGA GCC TGC CC -3’ 
m E-box s 5’- CAC CCT ATG TAC CCT GAC CGA ATT CCC AGT GGC AGC -3’ 
m E-box as 5’- GCT GCC ACT GGG AAT TCG GTC AGG GTA CAT AGG GTG -3’ 
m FP B1 s 5’- CTT GCC AGT GGC AGC TAA TTT TAG TCG ACC TTG GAG ATG CC -3’ 
m FP B1 as 5’- GGC ATC TCC AAG GTC GAC TAA AAT TAG CTG CCA CTG GCA AG -3’ 
m FP B2 s 5’- GCA GAG CTT AGA TCT GCC AGC AAG TGC AGA GGA TGT TGG -3’ 
m FP B2 as 5’- CCA ACA TCC TCT GCA CTT GCT GGC AGA TCT AAG CTC TGC -3’ 
m FKHR a s 5’- GGG TTC AAG GCA ACT TAA GGA GAT TCT ATA ACA GTA AGC TTA AAA  
ATC TGA TTA AAA CGC -3’ 
m FKHR a as 5’- GCG TTT TAA TCA GAT TTT TAA GCT TAC TGT TAT AGA ATC TCC TTA 
AGT TGC CTT GAA CCC -3’ 
m FKHR b s 5’- CTG ATT AAA ACG CAT CGT CGA CTA CTT GGG GTG GGG GGT GTC 
AGG GC -3’ 
m FKHR b as 5’- GCC CTG ACA CCC CCC ACC CCA AGT AGT CGA CTA TGC GTT TTA 
ATC AG -3’ 
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2.3.4 Oligonucleotides used for pGL3-SRE and SRE/SP construction 
The sequences of oligonucleotides comprising FAS-SRE and FAS-SP1 binding elements used 
to construct the pGL3-4SRE and pGL3-SR/SP are shown below.  
4 SRE s 5’- CAA  AAT CAC CCC ACT GCA AAA TCA CCC CAC TGC AAA ATC ACC 
CCA CTG AAT TCA AAA TCA CCC CAC TGC -3’ 
4SRE as 5’- TCG AGC AGT GGG GTG ATT TGA ATT CAG TGG GGT GAT TTT GCA 
GTG GGG GTG ATT TTG CAG TGG GGT GAT TTT GGT AC -3’ 
SR/SP s 5’- CAA  AAT CAC CCC ACT GCA AAA TCA CCC CAC TGC AAA ATC ACC 
CCA CTG AAT TCA ACT CCT CCC CCT GC -3’ 
SR/SP as 5’- TCG AGC AGG GGG AGG AGT GAA TTC AGT GGG GTG ATT TTGCAG 
TGG GGT GAT TTT GCA GTG GGG TGA TTT TGG TAC -3’  
 
2.4 Antibodies 
Antibodies Epitope Source Dilution Company 
Glucokinase 
(C-20) 
C-terminus of  h GCK Goat polyclonal 1:250 Santa Cruz 
SREBP AA 301-407 of SREBP-1 
Mouse 
monoclonal 
1:2000 Santa Cruz 
FOXO1 AA 471-598 of h FKHR Rabbit polyclonal 1:1000 Santa Cruz 
Acetylated 
FOXO1 
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2.5 Protease inhibitors  
Complete, Mini, EDTA free protease inhibitor cocktail tablets (Roche) inhibit a broad spectrum of 
serine and cysteine proteases. One tablet in 10 ml of extraction buffer is sufficient for the 
inhibition of the proteolytic activity of proteases such as serine, cystine, trypsin and acid 
proteases in 10 ml of extraction buffer. 
 
2.6 Enzymes 
2.6.1 Restriction endonucleases  
Type II restriction endonucleases to generate 5’ or 3’ sticky ends used in this study were 
obtained from TaKaRa and MBI Fermentas. The enzymes were used with optimized buffers 
supplied by the company. 
2.6.2 DNA and RNA modifying enzymes 
Enzyme      Company 
Taq DNA polymerase     TaKaRa  
T4 DNA ligase      MBI Fermentas  
T4 polynucleotide kinase    Amersham 
Shrimp alkaline phosphatase (SAP)   Roche 
T3 and T7 RNA polymerases    Roche 
RNase A (DNase-free)    Qiagen 
2.6.3 Enzymes used in glucokinase enzyme activity assays 
The enzyme glucose 6-phosphate dehydrogenase (G6PDH) converts glucose 6-phosphate to 6-
phosphogluconate, which in turn is converted into ribulose-5-phosphate by 6-phosphogluconic 
acid dehydrogenase (6PGDH). Both enzymes were obtained from Sigma-Aldrich.  
2.6.4 Collagenase 
The collagenase (Biochrom AG) is a protease which degrades collagen fibrils, which are the 
major fibrous component of animal extracellular connective tissue. The liver connective tissue 
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was digested with collagenase for the preparation of rat primary hepatocytes. Collagenase has 
no specific activity for any single substrate (single protein) but could recognize specific structural 
patterns inside protein chains. 
2.6.5 Lysozyme 
Bacterial cell wall was destroyed by using lysozyme (Applichem), which hydrolyzes the glycoside 
bond of the bacterial mureine.  
 
2.7 Stock Solutions 
All stock solutions were, unless mentioned, prepared in sterile deionized H2O at room 
temperature according to the laboratory manual ‘Molecular cloning’ (Sambrook and Russell). 
The solutions used for RNA studies were prepared with DEPC-treated H2O. 
Ammonium acetate 7.5 M      Final concentration 
NH4Ac     57.8   g / 100 ml   7.5 M 
The solution was autoclaved 
Ammonium per sulphate (APS)     Final concentration 
APS     100 mg / ml    10% 
APS was prepared fresh always. 
Blocking reagent 10%       
50 mg of blocking reagent was diluted in 500 ml of 1 X maleic acid buffer with little warming. The 
solution was autoclaved and stored at 4˚C. 
Lithium chloride 4 M       Final concentration 
LiCl     17 g / 100 ml    4 M 
The solution was autoclaved. 
Magnesium chloride 1 M      Final concentration 
MgCl2     20.33 g / 100 ml   1 M 
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The solution was sterile filtered. 
Sodium acetate 3 M (pH 5.2)      Final concentration 
NaAc     24.61  g    300 mM 
H2O     to 100 ml 
The pH was adjusted with concentrated acetic acid (needed in large amounts) to 5.2. The 
solution was autoclaved. 
Sodium acetate 2 M (pH 4.1)      Final concentration 
3 M NaAc    2 parts     2 M 
Acetic acid (Conc)   1 part    
The pH was adjusted with concentrated acetic acid to 4.1 and autoclaved. 
10 X PBS        Final concentration 
NaCl     81.82  g / l    1.4 M 
KCl     2.02    g / l    27 mM 
Na2HPO4             16.02   g / l    90 mM 
KH2PO4    2.04    g / l    15 mM 
The pH was adjusted to 7.0 and autoclaved. 
10 % SDS        Final concentration 
SDS     10 g / 100 ml    10 % 
20 X SSC        Final concentration 
NaCl     175.32 g / l    3 M 
Sodium citrate      88.25 g / l            0.3 M 
Tris/HCl 1M        Final concentration 
Tris     12.11 g / l    1 M 
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HCl was used to adjust different pH values 7.5; 8.0; 9.0 and the solutions were autoclaved.  
Tris/HCl 0.1 M        Final concentration 
Tris     1.211 g / l    0.1 M 
HCl was used to adjust different pH values 7.5; 8.0; 9.0 and the solutions were autoclaved.  
Ampicillin        Final concentration 
Ampcillin powder     1.25 g / 50 ml   25 mg / ml 
Adjusted the pH to 7.0 with NaOH and sterile filtered.  
Calcium chloride       Final concentration 
CaCl2.2H2O    3.675 g / 10 ml   2.5 M   
The solution was sterile filtered and stored at -20˚C 
Ethidium bromide       Final concentration 
EtBr     50 mg / 50 ml    10 mg/ml 
EDTA         Final concentration 
EDTA      18.6 g/ 100 ml    0.5 M 
Adjusted the pH to 8.0 and stored at RT. 
 
2.8 Chemicals 
Chemical         Company 
Acrylamide (30% acrylamide: N,N-methylene-bisacrylamide) Roth (Karlsruhe) 
Agar         Applichem (Darmstadt) 
Agarose        Invitrogen (Karlsruhe) 
Ammonium persulphate (APS)     Serva (Heidelberg) 
Ampicillin (Amp)       Serva (Heidelberg) 
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Antifoam A        Sigma (Taufkirchen) 
Bacto agar        Applichem (Darmstadt) 
Bacto trypton        Applichem (Darmstadt) 
Blocking reagent       Roche (Mannheim) 
Bromophenolblue       Serva (Heidelberg) 
Chloroform        Merck (Darmstadt) 
CDTA         Sigma (Taufkirchen) 
CSPD         Roche (Mannheim) 
Diethylpyrocarbonate (DEPC)     Roth (Karlsruhe) 
Dimethylsulfoxide (DMSO)      Sigma (Taufkirchen) 
Dithiothreitol (DTT)       Sigma (Taufkirchen) 
dNTPs         Roche (Mannheim) 
Ethanol        Merck (Darmstadt) 
Ethidium bromide (EtBr)      Serva (Heidelberg) 
Formaldehyde (37%)       Applichem (Darmstadt) 
Glycerol         Applichem (Darmstadt) 
Glycine        Applichem (Darmstadt) 
Guanidin  thiocyanate       Applichem (Darmstadt) 
Hepes         Applichem (Darmstadt) 
Insulin         Sigma (Taufkirchen) 
Isopropanol        Merck (Darmstadt) 
Luciferase cell lysis reagent      Promega (Mannheim) 
β-mercaptoethanol (β-ME)      Serva (Heidelberg) 
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Maleic acid        Applichem (Darmstadt) 
MEM, M199 medium       PAA (Cölbe) 
Nembutal        Sigma (Taufkirchen) 
NP-40         Applichem (Darmstadt) 
N-lauroylsarcosin       Sigma (Taufkirchen) 
3-(N-morpholin)-propanesulfonic acid (MOPS)   Applichem (Darmstadt) 
Non-fat dried milk       Applichem (Darmstadt) 
Paraformaldehyde       Serva (Heidelberg) 
Penicillin G potassium salt      Serva (Heidelberg) 
Phenol         Applichem (Darmstadt) 
Phenylmethanesulfonyl fluoride (PMSF)    Sigma (Taufkirchen) 
Ponceau S        Sigma (Taufkirchen) 
PEG 4000        Serva (Heidelberg) 
Sodium dodecyl sulfate (SDS)     Serva (Heidelberg) 
TEMED        Applichem (Darmstadt) 
Tris(hydroxymethyl)aminomethane (Tris)    Sigma (Taufkirchen) 
Triton X-100        Sigma (Taufkirchen) 
Trypan Blue        Sigma (Taufkirchen) 
Trypsin        PAA (Cölbe) 
Tween® 20        Applichem (Darmstadt) 
X-ray film developer LX24      Kodak (Rochester, USA) 
X-ray film fixer AL4       Kodak (Rochester, USA) 
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2.9 Detection, purification and synthesis kits 
Kit name       Manufacturer 
Jet star Plasmid purification Kit    Genomed (Löhne) 
QIAEXII Gel extraction Kit     Qiagen (Hilden) 
DIG-Nucleic-Acid detection kit    Roche (Mannheim) 
Luciferase Assay Kit      Berthold (Pforzheim) 
ECL-Kit       Amersham (Freiburg) 
Synthetic oligonucleotides 5’-end labeling Kit  MBI Fermentas (St.Leon-Rot) 
QuickChange XL Site-Directed Mutagenesis Kit  Strategene (Amsterdam) 
 
2.10 Consumables 
Product name       Company 
3MM whatmann paper     Whatman Biometra (Göttingen) 
Sterile syringe filters 0.2 µm     Sartorius (Göttingen) 
Vasofix Braunüle® 20 G 11/4 , 14 G 2    Braun (Melsungen) 
Electroporation cuvetts      BioRad (Munich) 
Nylon membrane Hybond-N+     Amersham Pharmacia (Freiburg) 
PVDF membranes ImmobilonTM P    Amersham Pharmacia (Freiburg) 
Tissue culture plastic ware Sarstedt (Nümbrecht), Eppendorf 
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2.11 Instruments 
Device name     Model    Company 
Autoclave             CE 087   Systec (Wettenberg) 
Auto Lumat (Luminometer)           LB 953   Berthold (Pforzheim) 
Automatic DNA Sequencer           373 A   Applied Biosystems (Weiterstadt) 
Beckman High speed centrifuge      J2-21   Beckman (USA) 
Electric power apparatus           P 25/30   Biometra (Göttingen) 
Electroporator             Gene Pulser II  BioRad (Munich) 
Electroblotting apparatus     Uni. Workshop 
Gel documentation            DigiDoc-It®  UVP (Cambridge)          
Heating shaker            Thermomixer 5436 Eppendorf (Hamburg) 
Heating stirrer             RCT basic  Kika labortechnik (Staufen) 
Hybridization ovens            OV 3   Biometra (Göttingen) 
Incubator with gas flow           Cytoperm 8080  Heraeus (Hanau) 
Incubator with shaking           3-25              New Brunswick Scientific  
        (Nuertingen)   
Microwave oven            KOR-6105  Daewoo Electronics (Butzbach) 
PCR thermocyclers            Gene Amp 2400 Perkin-Elmer (Langen) 
Peristaltic pump            Cyclo 1   Roth (Karlsruhe) 
pH meter             535 Multi Cal  Schütt Labortechnik (Göttingen) 
Photometer             λ UV/VIS  Perkin-Elmer (Langen) 
RNA-/DNA-calculator                   GeneQuant II  Pharmacia (Ratingen (Breitscheid) 
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Spectrophotometer            DU 640   Beckman® (USA) 
Speed Vac           Savant SC110  Schütt labortechnik (Göttingen) 
Sterile benchs           TL 2472, HB 2448 Heraeus (Hanau) 
Sterile pump           DBP Nr. P 24333991 Schleicher & Schüll (Dassel) 
Table-top centrifuges          5414 and 5415 C Eppendorf (Hamburg) 
Table-top cooling centrifuges         5403, 5415 R  Eppendorf (Hamburg) 
Thermostats           450 LE; Type R 10/2 Meßgeräte-Werk Lauda 
            5320   Eppendorf (Hamburg) 
Ultra-sound sonicator          Sonifier® B-12  Branson,(Schwäbisch Gmünd)   
Ultraviolet stratalinker          1800   Strategene (Amsterdam) 
Water bath           K2R; NB/S8  Meßgeräte-Werk Lauda 
Water deionization system     Bruno Kummer (Frieberg)  
X-Ray film cassettes          13 cm X 18 cm             Intas (Göttingen)   
 
2.12 Software 
Program Name       Company / Organization 
Doc It         UVP (Cambridge) 
BLAST         NCBI 
Corel Draw        Corel corporation 
MS office        Microsoft 
DNA star        Lasergene 
Image J        NIH 
Clone manager Suite 7               Sci Ed Central 
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3. Methods 
3.1 Cell Biology 
All cell lines used in this study were grown at 37˚C with humidified air containing 5% CO2, and 
16% O2 in a cell culture incubator. HepG2 and HEK293-T cell lines cultured in 175 cm2 cell-
culture flask were maintained in minimum essential medium supplemented with 10% (w/v) fetal 
bovine serum, 1% non essential amino acids (PAA) and 0.5% (w/v) antibiotic. For sub-culturing, 
a 80-90% confluent flask was rinsed twice with 10-15ml 1×PBS and except HEK cells, treated 
with 1% trypsin / EDTA for approximately 2-3 min and the reaction was stopped by adding 5 ml 
of growth medium with 10% FBS which contains trypsin inhibitors. Then the cells were harvested 
by centrifugation and the pellet was resuspended in 5 ml culture medium, counted in a Neubauer 
chamber and seeded onto plates at required ratios shown below. 
Purpose   Cell number/vol. suspension plated Ø of the culture dish     
Transfection    1× 106 / 1.5 ml    60 mm 
Protein isolation   2×106 / 3.0 ml    60 mm 
RNA isolation               3×106 / 9.0 ml            100 mm  
 
3.1.1 Isolation of primary rat hepatocytes 
Primary hepatocytes from the rat liver were isolated by the collagenase perfusion method, 
according to the method of Berry and Friend (1969) under aseptic conditions.  
3.1.1.1 Liver perfusion  
Male Wistar rats (~200-300 g) were housed a controlled environmental conditions with a 12 h 
light 12 h dark cycle (light from 07.00 to 19.00 h). They were fed ad libitum with standard 
laboratory diet (Altromin) and free access to water. Rats were anaesthetized with pentobarbital 
(60mg/kg body weight). Isolation of hepatocytes by liver perfusion is a two step process 
consisting of non-reciculative in situ pre-perfusion and recirculative collagenase perfusion.  
1. Non-reciculative in situ pre-perfusion of the liver: Following coeliotomy (an incision 
through the abdominal wall to gain access into the abdominal cavity), the hepatic portal 
vein was cannulated with a 1.3 × 45 mm size needle, and the pre-perfusion of the liver 
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was started with 150-200 ml pre-perfusion medium (Krebs-Ringer solution with EGTA) at 
a flow rate of 30 ml/min until the liver was free from blood. Then, the inferior vena cava 
was ligated just above the diaphragm to close the whole body circulation; the inferior 
vena cava was cut beneath the liver and cannulated with a 22 × 50 mm sized needle.  
2. Recirculative collagenase perfusion: The pre-perfused liver was now perfused with 
collagenase perfusion medium at a flow rate of 30 ml/min until the liver became soft, due 
to digestion of the connective tissue, which will take up to 10-15 min. During perfusion, 
the perfusate was returned to the reservoir via a plastic tube connected to the needle 
inserted in the inferior vena cava and recirculated. To prevent distension of the liver and 
possible cell damage, the rat was positioned about 10 cm above the reservoir, so the 
drainage of the liver could be assisted by a siphoning effect. 
Pre-perfusion and perfusion solutions were pumped through an oxygenator, from which they 
were directed into the portal vein with a pressure of 10-15 cm of water.     
Krebs Ringer stock solution      Final concentration 
NaCl     7          g/l   120.0 mM 
KCl     0.36     g/l       4.8 mM 
MgSO4 X 7 H2O   0.296   g/l       1.2 mM 
KH2PO4    0.163   g/l       1.2 mM 
NaHCO3    2.016   g/l     24.4 mM 
HEPES    3.356 g/l       15 mM 
The solution was equilibrated with carbogen and adjusted to pH 7.35. 
Preperfusion solution       Final concentration 
EGTA     0.1      g/l   0.25 mM 
Dissolved in Krebs Ringer stock solution. 
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Collagenase perfusion solution     Final concentration 
CaCl2 X 2 H2O   0.588  g/l   4 mM 
Collagenase    0.500  g/l    dissolved in Krebs Ringer stock solution. 
Collagenase was dissolved in Krebs Ringer stock solution just before the preparation of 
hepatocytes, equilibrated with carbogen (5% CO2 in Oxygen) for 30 min and finally sterile 
filtered. 
 
3.1.1.2 Preparation of the hepatocyte suspension 
Once persuion was done, the liver was carefully removed and transferred into a glass cup filled 
with 20-30 ml of culture medium M199 (PAA). The soft liver was then broken up with a blunt 
spatula and the Glisson’s capsule i.e. the outer capsule of connective fibrous tissue surrounding 
the liver was removed carefully. The obtained primary suspension was filtered through a nylon 
mesh with a pore size of 79 µm to remove the remainders of the Glisson’s capsule as well as big 
cell aggregates. The filtrate was then centrifuged for 3 times at 20 × g for 2 min to remove the 
non-parenchymal cells and cell debris. After the final centrifugation one gram wet weight of the 
sedimented cells was resuspended in about 50 ml of M199 to adjust the density of the cell 
suspension to about 106 / 2.5 ml. 
 
3.1.1.3 Culture of primary rat hepatocytes  
Freshly isolated hepatocytes resuspended in M199 were supplemented with 4% fetal calf serum, 
1% antibiotics (penicillin-strptomycine), 100 µM dexamethasone and 1 nM insulin as permissive 
hormones. Then they were plated as per the requirement and cultured in gas controlled 
incubators with a water vapour saturated atmosphere of 16% O2, 5% CO2 and 97% humidity at 
37˚ C. After the initial 4 h attachment phase (5 h for transfected cells) the medium was changed, 
and the hepatocytes were further cultured in M199 with the same concentrations of hormones 
and antibiotics as before, except fetal calf serum. A volume of 2.5 ml medium per 60 mm culture 
dish and 6 ml per 100 mm culture dish was added. After 24 h the medium was changed again 
and the culture was continued for another 19 h.   
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3.1.1.4 Hormone and antibiotic stock solutions 
All solutions were filter sterilized and stored at -20˚ C. 
Antibiotics  
Penicillin G, sodium salt   0.64 g/100 ml 
Streptomycine sulphate   1.17 g/100 ml 
Dissolved in 0.9% NaCl solution 
Dexamethasone (100 µM) 
Dexamethasone    3.92 mg/100 ml 
Dexamethasone was first dissolved in 0.5 ml of ethanol and then filled with 0.9% NaCl solution 
to 100 ml. 
Insulin (10 µM) 
Insulin       6 mg/100 ml 
Bovine serum albumin           100 mg/100 ml 
Insulin was dissolved in 0.9% NaCl at a pH of 2.5, neutralized and then bovine serum albumin 
was added.  
 
3.1.2 Transfection of hepatocytes, HepG2 and HEK293-T cells 
Primary rat heptocytes, HEK293-T and HepG2 cells were transfected by a modified calcium 
phosphate precipitation method (Graham and van der Eb, 1973). The modifications are mostly 
regarding the type of cells used, the time and duration of transfection {(Parker and Stark, 1979); 
(Chen and Okayama, 1987); (Chen and Okayama, 1988); (Ginot et al., 1989); (Pasco and 
Fagan, 1989); (Rippe et al., 1990)}.  The principle of the method is that the uptake of DNA is 
markedly enhanced when the nucleic acid is presented as a co-precipitate of calcium phosphate 
and DNA in the presence of a phosphate-buffered solution. The insoluble precipitate attaches to 
the cell surface and is brought into the cells by endocytosis. 
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Transfection mixture for one 60 mm dish               Final Concentration 
Plasmid DNA          2.5 µg 
H2O     to 67.5 µl     
2.5 M CaCl2          7.5 µl    125 mM 
2 X Hepes           75 µl     1 X 
The transfection mixture was prepared in polystyrol tubes to prevent adhesion of the DNA to the 
walls and was allowed to form the co-precipitate of DNA and calcium phosphate. Finally, 150 µl 
of the mixture was added to 1.5 ml of the freshly plated heptocytes in suspension or to 2.5 ml of 
precultured HepG2 or HEK293-T cells in 60 mm culture dishes. After 5 h transfection the 
medium was changed and the hepatocytes were further cultured in M199 with the same 
concentrations of hormones and antibiotics as mentioned except fetal calf serum. After 24 h the 
cells were grown for additional 24 h in fresh culture medium of 2.5 ml per 60 mm culture dish, 6 
ml per 100 mm culture dish and 17 ml per 150 mm culture dish. 
2 X Hepes        Final Concentration 
Hepes     1.2  g/100ml     50 mM 
NaCl      1.6  g/100ml             280 mM 
Na2 HPO4    0.3  g/100ml               1.5 mM 
The pH was adjusted with 5N NaOH to 7.05 and the buffer was stored at -20˚C as 10 ml 
aliquots.  
Calcium chloride 2.5 M      Final Concentration 
CaCl2      36.75 g/100ml    2.5 M 
The solution was filter sterilized and store in aliquots at -20˚C. 
 
3.1.3 Luciferase reporter gene assay 
Luciferase activity in the cells transfected with reporter vectors containing the luciferase gene 
from North American firefly (Photinus pyralis) was detected using the Luciferase Assay Kit 
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(Berthold, Pforzheim). The luciferase assay is based on the enzyme-catalyzed 
chemiluminescence where the firefly luciferase enzyme catalyses oxidative decarboxylation of 
luciferin in the presence of ATP and Mg2+ ions yielding photons as well as AMP, CO2 and 
oxyluciferine. The light emission measured at 562 nm depends on the concentration of the 
luciferase enzyme; therefore, it allows quantitative estimation of the expression level of the 
reporter gene. 
Prior to measure the cells were washed with 2.5 ml 1×PBS and 500 µl lysis buffer were applied. 
The cells were allowed to lyse on a shaker for approximately 30 min, scraped, vortexed and 
centrifuged for 2 min at 16 000 x g (14 000 rpm at a tabletop centrifuge eppendorf, rotor 5415C). 
In case of primary rat hepatocytes, the cell lysates were snap frozen in liquid nitrogen, 
subsequently thawed at RT and centrifuged. Twenty µl of the supernatant from the transfected 
cells were automatically mixed in the luminometer with 100 µl luciferase assay reagent, 
prepared directly before use by mixing equal parts of solution A and B. The reaction was 
measured 10 times for 2 s. The intensity of luminescence is constant for 20 s and then 
decreases with a half-life of 5 min. 
5X Lysis buffer        Final concentration 
Tris      25 ml of 1M     125 mM 
CDTA    10 ml of 200 mM    10 mM 
DTT    4 ml of 500 mM     10 mM 
Glycerol             115 ml of 85 %    50 % 
Triton X-100   10 ml of 100%     5% 
H2O    to 200 ml  
The pH was adjusted to 7.8 with H3PO4 and the solution was autoclaved.  
 
3.1.4 Freezing of cells 
Cells from an 80-90% confluent dish were trypsinized and resuspended in 2-3 ml of growth 
medium. Cells were then centrifuged at 1000 g for 2 min and resuspended in 1.0 ml of fresh 
culture medium. Then 0.5 ml of cells were aliquoted into cryovials and an equal volume of 
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medium containing 20% DMSO was added, to get a final concentration of 10%. The vials were 
kept on ice for 15 min, and then transferred to -20 ˚C for 4 h and then to -70 ˚C for 48-72 h. Cells 
were finally transferred to liquid nitrogen storage.  
 
3.1.5 Treatment of hepatocytes with different compounds 
Freshly isolated hepatocytes were allowed to attach for 5 h and culture medium was changed. 
After 24 h the hepatocytes were treated with insulin, TO-901317, resveratrol, glucagon, cAMP at 
different concentrations specified for each experiment. For Northern blots the cells were treated 
for 16 h, for Western blots and luciferase assays the cells were treated for 24 h before 
harvesting without changing the medium. 
 
3.2 Molecular biological methods 
3.2.1 Polymerase chain reaction 
The polymerase chain reaction (PCR) is an in vitro method for exponentially amplifying DNA 
fragments from a template DNA (Mullis and Faloona, 1987). PCR reactions were carried out in a 
buffer containing 10 mM Tris (pH8.8), 1.5 mM MgCl2 and 10 mM dNTP (each) were used per 
reaction, along with 2.5 U of thermostable DNA dependent DNA polymerase (Taq). The reaction 
volume was usually 50 μl. PCRs were carried out for 25-30 cycles, with a denaturing 
temperature of 95 ˚C for 1 min, annealing temperature of 50-55 ˚C for 1 min (depending upon 
the sequence of the primer), and extension temperature of 72 ˚C for 1-2 min depending upon the 
length of the product to be amplified. Products of the PCR reaction were analyzed on 1-2% 
agarose gels containing 0.2 mg/ml ethidium bromide. In cases where the reaction products were 
used for restriction digestion or sub-cloning, the PCR amplified fragments were purified through 
Qiagen PCR purification columns.  
A 50 µl of standard polymerase chain reaction mixture contains: 
Template DNA     10 ng    
10 X Taq buffer (with 1.5 mM MgCl2)     5 µl 
10 mM dNTPs (each)       1 µl 
10 pmol/µl primers               2.5 µl  
Taq polymerase                2.5 U 
H2O                                                                 up to  50 µl 
The PCR reaction was carried out in a programmable thermal cycler (Perkin Elmer). 
Methods  39 
 
3.2.1.1 Purification of PCR products    
The PCR products were purified from the reaction mixture by sodium acetate/ethanol 
precipitation or by separating the PCR products on an agarose gel and the fragments of interest 
were purified using QIAquick gel extraction kit (Qiagen) following the manufacturer protocol. The 
purified PCR products were cloned into a T/A cloning vector and subcloned into pGL3-Basic by 
using the following methods. 
 
3.2.1.2 Cloning of PCR fragments into (pTZ57R/T) the T/A cloning vector    
The T/A cloning system is a convenient system for direct one-step cloning of PCR-amplified 
DNA fragements. DNA polymerases, that lack 3’→5’ exonuclease activity possess 
deoxynucleotidyl transferase (TdT) activity in addition to primer extension activity which 
frequently results in the addition of extra adenines at 3’-ends of amplified DNA molecules. This 
makes it possible to clone the PCR product directly into a linearized cloning vector with single 3’ 
–T overhangs. The 3’-A overhangs of the PCR product complement the 3’-T overhangs of the 
vector and allow fast ligation by T4 DNA polymerase. This ligation mixture can then be 
transformed into competent bacterial cells. 
A ratio of 1:3 vector to insert was used for ligation reaction. 
Ligation of PCR product into T/A Vector: 
Plasmid vector pTZ57R/T (~0.150 µg)   3 µl 
Purified PCR fragment     (~0.450 µg)   4 µl 
10X ligation buffer      3 µl 
PEG 4000 solution      3 µl 
Deionized water         to   29 µl 
T4 DNA ligase, 5U       2 µl 
The ligation reaction was incubated at 20 ˚C for 1 h.  T4 DNA ligase catalyzes the formation of a 
phosphodiester bond between free 5’-phosphate and 3’-OH groups of double-stranded DNA 
fragments resulting in the formation of recombinant DNA molecules. The ligation reaction occurs 
when the ends are compatible; at least one of the ends must be phosphorylated; ATP and 
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optimal ligation buffer are available. The ligation reaction was carried out at 20˚C for one h. Then 
8 to 10 µl of the reaction mixture was chemically transformed into competent E.coli cells. 
 
3.2.1.2.1 Subcloning 
Subcloning is a technique used to move a particular gene of interest from a parent vector to a 
destination vector in order to further study its functionality. In our case the PCR fragments 
cloned into the T/A cloning vector were excised with suitable restriction enzymes and subcloned 
into dephosphorylated pGL3 Basic vector.  
 
3.2.1.2.2 Dephosphorylation of linearized vector 
To prevent the recircularization of a linearized plasmid vector in ligation reactions, an enzymatic 
removal of 5’-terminal phosphate residues using shrimp alkaline phosphatase (SAP) was 
performed in 10 X SAP dephosphorylation buffer (Roche) for 1 h at 37 ˚C. The reaction was 
stopped by heating the sample at 65 ˚C for 10 min and the DNA fragments were purified from 
agarose gel pieces using QIAquick Gel Extraction Kit (Qiagen) and quantified against a λ-Hind III 
DNA ladder. 
 
3.2.2 In vitro site-specific mutagenesis 
Site directed mutagenesis is an invaluable PCR based technique used to generate a mutation at 
a defined site in a DNA molecule to understand the gene expression and protein structure-
function relationships. The QuikChangeR XL site-directed mutagenesis kit (Stratagene) was 
used to create the point mutations in putative transcription factor binding elements. The 
procedure to generate the point mutations was carried out according to the manufacturer 
instruction manual. 
 
3.2.3 Synthetic double stranded oligonucleotide cloning into pGL3 promoter 
vector  
Artificially synthesized oligonucleotides containing the FAS-4SRE’s and FAS-3SRE1SP were 
cloned into Xho I and Kpn I restriction sites of the pGL3-promoter vector. The cloning procedure 
had the following steps: 
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Preparation of oligonucleotides for cloning into pGL3 promoter vector      
Both sense and antisense oligodeoxynucleotides which had to be cloned were phosphorylated 
at their 5’-ends by T4 polynucleotide kinase. Phosphorylated sense and antisense 
oligonucleotides were annealed in a 1.5 ml tube. The annealing reaction was carried out in a 
water bath heated up to 90 ˚C. Then the water was allowed to cool to room temperature for at 
least 6 h, which facilitates the annealing of oligodeoxynucleotides. The annealed 
oligodeoxynucleotides were precipitated with NaAc/ethanol. The precipitated ds-
oligodeoxyribonucleotides were washed with 70% ethanol, dried under vacuum and dissolved in 
30 µl H2O. One µl of annealed mixture was checked on a 10% native acrylamide gel. 
Phosphorylation of ss-oligodeoxynucleotide  
Oligo (sense or antisense)      2 µg 
5 X ligase buffer (5 mM ATP)          4 µl 
T4 polynucleotide kinase (10 U/µl)              1.5 µl 
H2O              to  20 µl 
The mixture was incubated at 37 ˚C for 60 min. 
Polyacrylamide gels allow much better separation of DNA fragments than agarose gels. They 
can separate molecules of DNA whose lengths differ only by 1 bp in 1000 bp. The annealed 
samples were loaded on native acrylamide gel and electrophoresis in 1 X TBE buffer for 30 min 
at 15 mA was performed. Then, the gel was soaked for 10 min in ethidium bromide solution (10 
µl ethidium bromide in 10 ml of 1 X TBE buffer) and the DNA was visualized under UV light. 
10% Acrylamide gel (85 mm x 90 mm x 0.8 mm)   Final Concentration 
Acrylamide   3.3 ml (RotiphoreseRGel30 (10 % Acrylamide/0.8 % Bisacrylamide) 
TBE    0.5 ml 20 X TBE buffer  1 X TBE 
H2O    to 10 ml 
TEMED   2 µl 
10%  APS   70 µl 
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20 X TBE        Final Concentration 
Tris               108.99 g/l, pH 8.5   900 mM 
Borate      55.94 g/l,    900 mM 
EDTA        7.44 g/l      20 mM 
Preparation of the pGL3-Promoter vector for ligation 
The pGL3-Promoter vector was linearized with Xho I and Kpn I. To prevent religation of the 
linearized vector its 5’-ends were dephosphorylated by adding SAP to the restriction mixture and 
further incubation for 1 h at 37 ˚C. After one hour the SAP activity was inactivated by heating the 
reaction at 65 ˚C for 10 min. 
The dephosphorylated mixture was loaded on to a 1% agarose gel and the linearized vector was 
isolated from the agarose gel with the QIAEX II Gel Extraction Kit (Qiagen) and quantified.  
Ligation of annealed oligonucleotides into linearized pGL3-Promoter 
The 5’-phosphorylated ds-oligodeoxynucleotides were ligated into the linearized and 
dephosphorylated pGL3-Promoter vector by T4 ligase. The enzyme can only catalyze binding of 
the 5’-phosphorylated ends of the ds-oligodeoxynucleotides with the 3’-OH ends of the vector; 
the 3’-OH ends of the ds-oligodeoxynucleotide and the 5’-dephosphorylated ends of the vector 
could be ligated only by the specific enzymes present in E.coli. Therefore E.coli cells were 
transformed with the ligation mixture immediately after ligation reaction. The ligation reaction 
was incubated at 16˚C and then transformed in competent E.coli cells. 
Ligation reaction 
ds-oligonucleotide (5’-phosphorylated)   100 ng 
Vector     (5’-dephosphorylated)     50 ng 
5 X ligase buffer (5 mM ATP)         4 µl 
T4 ligase     (1 U/µl)      0.5 µl 
H2O                 to 20 µl   
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3.2.4 E.coli competent cell preparation  
Competent cells are bacteria which can accept extra-chromosomal DNA or plasmids. In nature, 
bacterial cells do not have the ability to accept foreign DNA from the surroundings. But bacterial 
cells can be made competent in several ways for transformation with the external plasmids. A 
single colony of E.coli strain XL1 blue was inoculated in 5ml LB medium and cultured overnight 
at 37˚C with moderate shaking. This pre-culture was inoculated into 500 ml of LB medium (1:100 
dilution) and allowed to grow while shaking until they reached an OD550 of 0.4-0.5 (3-5h). The 
bacterial cells were harvested by centrifugation at 1000 x g for 15 min (2500 rpm, Beckman GSA 
rotor). The pellet was washed with 1/10 volume (5-10 ml) of ice cold TSS buffer (1% (w/v) NaCl, 
1% (w/v) tryptone, 0.5% (w/v) yeast extract, 30 mM MgCl2, 10% (w/v) PEG 4000, 5% (v/v) 
DMSO, pH 6.5, sterile filtered). The cells were aliquoted into 100 µl volumes, frozen in an 
ethanol/CO2 bath and stored at -80 ˚C. 
For the preparation of electrocompetent cells, cells were grown to reach 0.6-0.8 OD600 and 
centrifuged for 15 min at 3500 x g (4800 rpm, Beckman GSA rotor). The pellet was washed 
twice with ice-cold 10% glycerol at 4000 x g for 15 min (5000 rpm, Beckman GSA). The pellet 
was dissolved and aliquoted into volumes of 100 µl, immediately frozen in liquid N2 and stored at 
-80˚C. 
LB medium 
Trypton   10 g/l 
Yeast extract     5 g/l 
NaCl    10 g/l 
The pH was adjusted with NaOH to 7.3. The medium was autoclaved after preparation. 
The efficiency of the competent cells was tested by a test transformation with a plasmid carrying 
ampicillin resistance gene.  
 
3.2.5 Transformation of competent E.coli cells 
An aliquot of 100 µl competent cells was thawed on ice, the ligation mixture or the plasmid DNA 
which had to be transformed was added carefully, the sample was mixed gently by tapping the 
eppendorf and then incubated on ice for 30 min. After a 2 min heat shock at 42˚C, the cells were 
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cooled on ice for 10 min. Then 500 µl of SOC medium was added and the culture was cultured 
for 45 min at 37˚C on a roller. A 200 µl aliquot was plated on an LB agar dish containing 
ampicillin and incubated at 37˚C overnight.  
In case of electroporation the DNA was introduced into electrocompetent E.coli cells by exposing 
them to a short-high-voltage (2.5 volts) electrical discharge.  
 
3.2.6 Ampicillin agar dishes  
500 ml of LB medium containing 6.25 g of bactoagar was autoclaved. After cooling to 50 ˚C 
ampicillin was added to the final concentration of 40 µg/ml. A ten ml of the LB-agar with 
ampicillin was plated into sterile petri dishes and allowed to solidify under a sterile hood. The 
dried dishes were stored in dark at 4˚C. 
 
3.2.7 Isolation of plasmid DNA (mini preparation) 
Transformed bacterial colonies with the ligation mixture or with a plasmid, grown on LB-
ampicillin agar plates, were inoculated with 5 ml ampicillin containing LB medium. Plasmid DNA 
was isolated from the 5 ml culture by minipreparation. 
Three ml of the bacterial culture was centrifuged in a table top centrifuge at 3000 x g (6000 rpm 
in a tabletop centrifuge eppendorf, rotor 5415C) for 10 min. The medium was drained and the 
bacterial pellet was resuspended in 150 µl of sterile TELT-solution and 3 µl of the lysozyme (50 
mg/ml in 10 mM Tris/HCl pH 7.5, 0.1 Mm EDTA) was added for efficient lysis of the cells. The 
solution was mixed well and heated at 95˚C for 2 min and cooled on ice. The resulting bacterial 
lysate was centrifuged at 16 000 x g for 10 min (14 000 rpm at a tabletop centrifuge eppendorf, 
rotor 5415C) to remove the bacterial debris. The supernatant containing the plasmid DNA was 
precipitated by adding 100 µl isopropanol (10 min at -20˚C) and centrifuged at 16 000 x g (14 
000 rpm at a tabletop centrifuge eppendorf, rotor 5415C) for 20 min. The precipitated plasmid 
DNA was washed with 70 % (v/v) ethanol and centrifuged for 5 min. The pellet was air-dried for 
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TELT buffer        Final concentration 
Tris/HCl, pH 7.5       50 mM  
EDTA                 62.2 mM 
LiCl                   2.5    M 
Triton-X-100                  0.4% (v/v) 
The buffer was autoclaved and stored at room temperature. 
3.2.8 Restriction digestion 
Restriction analysis of DNA was performed by using type II restriction endonucleases, which 
generate fragments with 5’, 3’ sticky overhangs or blunt ends after digestion. The reactions were 
set in appropriate buffers optimized for the enzyme (s) and supplied by the manufacturer 
(TaKaRa and MBI Fermentas) 
Restriction mixture: 
Plasmid DNA       3 - 5 µl 
10 X buffer (Enzyme specific)        2 µl 
Restriction enzyme (10 U/µl)      0.5 µl 
Deionized water            to   20  µl   
The reaction mixture was kept at 37˚C for an h and the restriction digestion product was 
analyzed by agarose gel electrophoresis. The reaction sample was mixed with 3 µl of loading 
buffer and loaded onto a 1 % agarose gel. To determine the size of DNA fragments a DNA 
molecular weight standard was used. The electrophoresis was performed for 20-30 min with 50 
volts/cm. The negatively charged DNA migrated from the cathode (-) to anode (+). To visualize 
DNA, the gel was treated with ethidium bromide which intercalates between the bases of DNA 
double strands forming a complex fluorescent under UV light. 
For preparation of the 1 % gel, 1 g of agarose was dissolved by boiling in 100 ml of 1 x TAE 
buffer. After the agarose solution was cooled to 60 ˚C it was poured into a gel chamber (8 cm X 
5 cm X 0.4 cm). The restriction samples were loaded onto the gel pockets. When the 
electrophoresis was finished, the gel was soaked in 500 ml of 1 X TAE buffer with 10 µl of 
ethidium bromide and the bands were detected under UV light (245 nm). The DNA fragment 
profile was visualized under UV light and photographed. The estimation of the sizes and amount 
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of the DNA fragments was done by comparison with a size standard marker (1 kb DNA ladder, 
100 bp ladder) 
Ethidium bromide solution 
Ethidium bromide    10 mg/ml 
Stored at 4˚C, protected from light. 
10X TAE (Tris/Acetate/EDTA)      Final concentration 
Tris      6.1   g/100 ml      0.5  M 
Sodium acetate   1.6   g/100 ml      0.2  M 
EDTA     0.7   g/100 ml     0.02 M 
The pH was adjusted with acetic acid to 7.4, the buffer was autoclaved. 
Loading Buffer        Final concentration 
Bromophenol blue   0.01 g/100 ml      0.01 % 
Glycerol    40 ml/100 ml       40 % 
10 x TAE buffer   10 ml/100 ml       1 X 
The buffer was autoclaved and stored at 4 ˚C. 
 
3.2.9 Isolation of plasmid DNA in large scale (Maxipreparation) 
For the preparation of larger amounts of high copy plasmids, the DNA Jet Star Maxi-kit 
(Genomed) was used. The isolation procedure was carried out according to the manufacturer’s 
instructions. (Genomed Plasmid Purification Handbook, 2000) 
 
3.2.10 Estimation of nucleic acid concentration 
The concentration of nucleic acids was determined using a spectrophotometer (GeneQuant, 
Pharmacia) by measuring the absorption at 260 nm of 100 fold diluted samples in a quartz 
cuvette. An OD260 of 1 in a case of 1 cm cuvette corresponds to 50 µg/ml double-stranded DNA, 
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40 µg/ml RNA, 37 µg/ml single-stranded DNA and 30 µg/ml oligonucleotides (Sambrook et al., 
1989). 
The ratio between A260/A280 is used to estimate the purity of the nucleic acid, since proteins 
absorb at 280 nm because of the aromatic character of tryptophan, tyrosine, histidine and 
phenylalanine that absorb light at 280 nm (Millinder & Clack). DNA or RNA preparations with a 
ratio of OD260/OD280 in the range of 1.8-2.0 were regarded as pure and protein-free. Absorption 
at 230 nm reflects contamination of the sample by substances such as carbohydrates, peptides, 
phenols or aromatic compounds. For pure samples the ratio between OD260/OD230 should be 
approximately 2.2. 
 
3.2.11 Plasmid Sequencing 
The sequence of the cloned DNA fragments was checked by using BigDyeTM Terminator 
Enhanced Terminators Cycle Sequencing kit from Perkin-Elmer, based on the chain-termination 
principle (Sanger et al., 1992). A premix solution containing 4 dideoxynucleotides (terminators) 
whose incorporation in the newly-synthesized complementary chain leads to an premature 
interruption of its elongation. The four terminators are labeled with four different fluorescent dyes 
and the terminated chains can be specifically detected by capillary electrophoresis on an ABI 
Model 373A capillary sequncer (Applied Biosystems) during which 40 mW argon lasers (488 nm 
and 514 nm) stimulate the fluorescence of dye-labeled polynucleotides. 
Sequencing reaction       Final Concentration 
Plasmid    2-3 µl     300-500 ng 
Primer (2.5 pmol/µl)   2    µl            5 pmol 
Sequencing mix   3    µl    
Deionized water         to 10   µl  
The sequencing reaction was subjected to 25 cycles of 30 sec at 96˚C; 15 sec at 55˚C; 4 min at 
60˚C in a thermocycler. The sequencing reaction products were precipitated by NaAc/Ethanol 
method. Thus precipitated sequencing reaction product was washed with 70 % ethanol and 
vacuum dried for 5 min and resuspended in 25 µl of deionized water. After denaturation for 2 
min at 95˚C and immediate cooling on ice, the sample was transferred into a special tube for 
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sequencing and kept on ice until loading on an ABI-prismTM 310 capillary electrophoresis 
sequencing station (Perkin-Elmer) for analysis. 
 
3.2.12 Preparation of digoxigenin-labeled RNA probes 
The detection of mRNA on northern blots was performed after hybridization with digoxigenin 
labeled, single-stranded RNA probes. The RNA probes were synthesized by an in vitro 
transcription catalyzed by T3, T7 and SP6 RNA polymerases. The plasmids containing the target 
gene sequence were linearized by a restriction enzyme allowing generation of uniform length of 
transcripts. The RNA probes were synthesized with the DIG-RNA-labeling kit (Roche, 
Mannheim). One digoxigenin-11-uridinemonophosphate (DIG-UMP) residue is incorporated 
approximately every 20-25 nucleotides. 
Digoxigenin labeled RNA probes for glucokinase, SREBP-1a, and β-actin, were prepared from 
the vectors pBS-GK, pcDNA 3.1 SREBP1Δ90, and pBS-actin which were linearized by HindIII, 
Kpn I and Xba I, respectively. 
In vitro transcription  
Linearized plasmid      11 µl  (~10 µg) 
10 X transcription buffer       2 µl 
10 X labeling mix (ATP, CTP, GTP, UTP, DIG-UTP)   2 µl 
RNasin (40 U/µl)        1 µl 
T7/T3 RNA polymerase (20 U/µl)      2 µl 
DEPC-H2O         2 µl 
The reaction mixture was incubated at 37˚C for 1.5 h. Then 0.5 µl of RNA polymerase was again 
added and the incubation was prolonged for another 1 h. Synthesized digoxigenin-labeled RNA 
was precipitated with 2.5 µl 4 M LiCl and 75 µl absolute ethanol at -20˚C for at least 2 h. After 
centrifugation at 4˚C, 12 000 x g (10 000 rpm, ss-34 rotor) for 10 min, the pellet was washed with 
80% ethanol and dried in a speed-vacuum. The pellet was dissolved in 100 µl DEPC-H2O and 
stored at -20˚C. 
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Estimation of labeling efficiency  
The labeling efficiency of the probe was estimated by comparing the DIG-labeled probe with a 
DIG-labeled control DNA provided in the labeling kit. The freshly labeled transcript (1 µl) as well 
as the digoxigenin-labeled control DNA (0.04-5 ng) was spotted on a nylon membrane 
(Amersham). The nucleic acids were cross-linked to the membrane in an UV cross-linker for 2 
min at 1200 µJ. The membrane was washed for 5 min in buffer 1 and incubated with 1 % 
blocking reagent for 20 min. The membrane was then incubated for 20 min in 20 ml of anti-
digoxigenin antibody solution (1:10000 in 1 % blocking reagent). The unbound antibody 
conjugate was removed by washing the membrane twice in buffer 1 for 15 min. After 2 min 
equilibration in buffer 3, the color substrate solution containing 45 µl NBT and 35 µl of X-
phosphate in 10 ml of buffer 3 was added. The color spots started to appear within 3 min. The 
reaction was stopped by washing the membrane with TE buffer.    
NBT         Final concentration 
NBT    74 mg/ml in 70% DMF  0.41 mM 
The solution was stored at -20˚C and protected from light. 
X-phosphate        Final concentration 
X-phosphate   50 mg/ml in DMF   0.38 mM 
The solution was stored at -20 ˚C. 
 
3.2.13 Isolation of RNA from primary rat hepatocytes 
Total RNA from primary rat hepatocytes was isolated by a modified method described by 
Chomczynski and Sacchi (Chomczynski and Sacchi, 1987). After a combined 
phenol/chloroform/isoamyl alcohol extraction the RNA was precipitated from the water phase 
and further purified by washing in ethanol. 
2 X 106 cells cultured on 60 mm culture dishes were washed twice with 0.9% NaCl. The cells 
were scraped with a disposable cell scraper in 1.5 ml of PeQLab buffer, homogenized by 
pipeting up and down and transferred into 2 ml cryocups. 300 µl of chloroform was added and 
mixed gently by inverting the tubes. The tubes were incubated at room temperature for 10 min 
and centrifuged at 10000 g for 15 min at 4 ˚C. The upper phase having RNA was transferred to 
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new 2 ml tubes containing 750 µl of isopropanol and the RNA was precipitated for 15 min at 
room temperature. After centrifugation at 10000 g for 15 min at 4 ˚C the RNA pellet was washed 
twice with 1 ml of ice cold 75% ethanol. The purified RNA was dried in a vacuum centrifuge for 5 
min and dissolved in 40 µl 0.1% SDS. The concentration of RNA was measured and stored at -
20˚C. 
Solutions for RNA isolation 
All the solutions for RNA experiments were prepared with DEPC-H2O. By addition of DEPC to 
deionized water for 12 h RNases in water were inactivated. Then the water was autoclaved. 
GTC buffer         Final Concentration 
Guanidinium thiocyanate    48.2 g    4 M 
Sodium citrate (1M)      2.5 ml              25 mM 
N-lauroyl sarcosine       0.5 g    17 mM 
2-mercaptoethanol      0.7 ml   0.1 M 
30 % antifoam A     0.33 ml   0.1 % 
DEPC-H2O              to 100 ml 
The solution was warmed for 30 min at 65˚C. The pH was adjusted with 1 N NaOH to 7.0 and 2-
mercaptoethanol was added at the end. 
PeQLab Buffer 
Phenol (water saturated)      8 ml 
NaAc (2M) pH 4.1    0.2 ml 
GTC buffer     10 ml 
DEPC-H2O       up to 20 ml 
Phenol (water saturated) 
2/3 volume of phenol was mixed with 1/3 volume of H2O. After phase separation the solution 
was stored at 4˚C and protected from light. 
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3.2.14 Northern blot analysis 
Northern blot is one of a series of blotting techniques used to transfer RNA onto a carrier to 
quantify RNA expression. The Northern blot takes its name from its predecessor, the Southern 
blot, which was named after the biologist Edwin Southern. In Northern blot, RNA is separated in 
a denaturing agarose gel, transferred by capillary transfer to a nitrocellulose membrane (vacuum 
blot) and fixed by UV crosslinking. The RNA of interest is identified by hybridization with a 
specific RNA probe. In order to prevent the contamination with RNases all the solutions used in 
Northern blot were autoclaved and the apparatus used for electrophoresis were kept in 3% H2O2 
for 1 h before use. 
3.2.14.1 Denaturation of RNA 
The RNA samples to be analyzed on a blot having 30 µg and 16.5 µl of loading buffer were 
denatured at 68 ˚C for 20 min and subsequently cooled on ice for 2 min. The denatured RNA 
samples were loaded on a denaturing formaldehyde agarose gel along with 5 µl of sample 
buffer. 
Loading buffer         Final concentration 
Formamide     15 ml      66.6% 
14.3 X MOPS                2.1 ml     26.7 mM 
37% formaldehyde    5.4 ml        8.9% 
The buffer was aliquoted and stored at -20 ˚C. 
14.3 X MOPS         Final concentration 
MOPS      5.93 g     286 mM 
NaAc      0.58 g       7.1 mM 
EDTA      0.5 g       1.3 mM 
DEPC-H2O          to 100 ml    
The pH was adjusted with NaOH to 7.0 and the solution was autoclaved. 
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Sample buffer         Final concentration 
Glycerin     5 ml      50% 
0.5 M EDTA     20 µl        1 mM 
Bromophenol blue              10 mg       0.1% 
DEPC-H2O    to 10 ml  The buffer was aliquoted and stored at -20 ˚C. 
3.2.14.2 Denaturing agarose gel electrophoresis of RNA   
Denatured RNA samples were resolved on a 1.5% formaldehyde agarose gel and 
electrophoresis was performed at 110 volts for 2 h. For preparation of a 1.5% gel 1.2 g agarose 
were dissolved in 65 ml DEPC-H2O. Then 8 ml of 10 X MOPS and 6.7 ml of formaldehyde were 
added. After mixing, the gel was poured into the prepared gel plate (10 X 14 cm) and allowed to 
solidify at room temperature. Then the gel was transferred into an electrophoresis chamber filled 
with 1 X MOPS buffer.  
After gel electrophoresis the formaldehyde was washed out by shaking the gel in 150 ml of a 1% 
glycine solution for 20 min. To visualize the RNA under UV light (254 nm) 5 µl of ethidium 
bromide was added and the gel was further incubated for 5 more min. Two main bands 
corresponding to 28S and 18S ribosomal RNA were visible under UV light, then the gal was 
photographed. Finally, the gel was washed in 20XSSC for 20 min before blotting onto a nylon 
membrane.   
10 X MOPS        Final concentration 
MOPS     41.9 g    200 mM 
NaAc       4.1 g       50 mM 
EDTA       3.7 g       10 mM 
DEPC-H2O             to 1 l 
The pH was adjusted to 7.0 with NaOH. The solution was autoclaved. 
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3.2.14.3 RNA blotting onto nylon membrane 
The resolved RNA in the gel was transferred onto a nylon membrane (Hybond N+, Amersham) 
by capillary blotting. The nylon membrane was presoaked in 2 X SSC for 10 min. The blotting 
equipment was prepared in the following way; A plastic tray filled with 700 ml of 10 X SSC 
buffer, a flat surfaced glass stand was fixed above the buffer level and covered with three layers 
of 3 mm thick filter paper (presaturated in 20 X SSC) with their ends dipped in the buffer 
underneath; RNA gel with the upper side downwards and surrounded by foil stripes to prevent 
drying out of papers; the nylon membrane was put on top of the gel; 3 layers of 3 mm filter 
papers with the size of the gel; approx. 10 cm of paper towels; an equally distributed weight of 
approx. 1 kg. The capillary blotting was carried out for at least 16-18 h, the arrangement was 
dismantled and the RNA was irreversibly cross-linked by UV radiation in an UV cross-linker 
(Stratagene) for 2 min at 1200 µJ. 
3.2.14.4 Hybridization of RNA with digoxigenin-labeled RNA probes 
The RNA blot was placed in a hybridization glass tube and pre-hybridized with 10 ml of 
hybridization solution at 65-68˚C in a hybridization oven. After 1 h of incubation, the pre-
hybridization solution was replaced with the 10 ml of hybridization solution containing 150 ng of 
digoxigenin-labeled antisense RNA probe. The hybridization was performed at 65˚C overnight. 
The unbound probe was removed by washing with 2 X SSC / 0.1% SDS for 2 X 5 min and 0.1 X 
SSC / 0.1% SDS for 2 X 15 min at 65˚C. 
Pre- and hybridization solutions        Final Concentration 
Deionized formamide    12.5 ml    50%   (v/v) 
10 % blocking reagent        6 ml               2.5%   (w/v) 
20 % SDS         25 µl             0.02%  (w/v) 
10 % N-lauroylsarcosine      250 µl     0.1%  (w/v) 
20 X SSC     6.25 ml    5 X 
The solution was stored at 4˚C. 
 
 
Methods  54 
 
3.2.14.5 Detection and quantification 
The detection of hybrids between the RNA of interest and the digoxigenin-labeled asRNA was 
performed using anti-digoxigenin antibodies conjugated to alkaline phosphotase (enzyme 
immunoassay). During the following dephosphorylation of dinatrium 3-(4-methoxyspiro[1,2-
dioxetane-3,2-(5’-chloro)tricycle{3.3.1.13.7}decan}-4-yl)-phenylphosphat (CSPD) by alkaline 
phosphatase a chemiluminescent unstable product was formed which produced light of 477 nm. 
This light signal can be recorded on X-ray films. The quantification was made densitometrically. 
The detection was performed with the DIG nucleic acid detection kit (Roche) according to the 
manufacturer instructions. After hybridization and posthybridization washes of the nylon 
membrane it was equilibrated in 1 X maleic acid buffer for 1 min. To prevent nonspecific binding 
of the DIG antibody to the membrane it was washed for 30 min in 100 ml 1% blocking reagent 
(10% blocking reagent diluted to 1% with 1 X maleic acid buffer). Then, the nylon membrane 
was incubated for 30 min at room temperature in 20-30 ml diluted antibody solution (anti-
digoxigenin Fab fragments, conjugated to alkaline phosphatase, in 1% blocking reagent at a 
concentration of 75 mU/ml = 1:10000 dilution which is equal to 5 µl antibody in 50 ml 1% 
blocking reagent). The unbound antibody was removed by washing in maleic acid buffer, 
containing 0.3% Tween – 2 X 15 min. The washed membrane was equilibrated in buffer 3 for 1-2 
min and wrapped in transparent foil along with the diluted CSPD solution for 5 min. (CSPD in 
buffer 3 at a concentration of 2.5 mM =1:1000 = 1 µl CSPD in 1 ml buffer 3). The liquid was 
completely removed and the membrane was incubated for 10 min at 37˚C. Then the membrane 
was exposed to a X-ray film for 30-90 min.  
For quantification of the RNA bands, IMAGE J software was used. 
Buffer 1 (Maleic acid buffer)        Final concentration 
Maleic acid    11.61  g    0.1   M 
NaCl      8.78   g    0.15 M 
H2O              to  1 l 
The pH was adjusted to 7.5 with solid NaOH. The solution was autoclaved. 
Buffer 2    450 ml of buffer 1 
     50 ml 10 X blocking reagent 
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Buffer 3         Final concentration 
Tris     12.11  g    0.1  M 
NaCl      5.84   g    0.1  M 
MgCl2     10.17  g    50   mM 
H2O                to 1 l 
The pH was adjusted with HCl to 9.5. Then the buffer was autoclaved and sterile filtered, MgCl2 
was added at the end.  
3.3 Biochemical methods 
3.3.1 Total protein isolation from the cultured cells 
Cultured cells were washed twice with 1 X PBS and scraped off the plate into 150 µl lysis buffer. 
The cells were destroyed thoroughly by ultrasonication on ice for 10 min or 25 min for primary 
hepatocytes respectively. The sonicated samples were centrifuged at 4 ˚C, 10 000 x g (12 000 
rpm, SS-34 rotor) for 20 min. The supernatant was collected into a new tube. The concentration 
of the protein from the cell lysate was measured with Bradford method. 
Lysis buffer        Final concentration 
Tris/HCl pH 8.0 (1M)   12.5 ml    50     mM 
EDTA (0.5)      2.5 ml      5     mM 
NaCl (5M)      7.5 ml             150     mM 
NP-40     1.25 ml    0.5% (v/v) 
H2O        up to 250 ml 
DTT     100 µl       5 mM 
Protease inhibitor cocktail tablet (Roche)     1/10 ml buffer 
DTT and protease inhibitor tablet was added freshly before use. Lysis buffer without DTT and 
protease inhibitor tablet can be stored at 4 ˚C. 
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3.3.2 Estimation of protein concentration  
Protein concentration from cell lysates was measured by a colorimetric assay (Bradford, 1976), 
which is based on a spectral shift in the absorption maximum (from 465 nm to 596 nm) of the 
coomassie Briliant Blue G-250 dye upon its binding to hydrophobic residues in the proteins. Two 
µl of cell extracts and water up to 100 µl was mixed with 1 ml of Bradford reagent incubated for 5 
min at RT. The optical density of the samples was measured at 578 nm. A water dilution of pure 
Bradford reagent was used as a blank control. Protein concentration of the samples was 
calculated with the help of a standard curve derived from different BSA protein amounts (2 µg, 4 
µg, 6 µg, 8 µg, 16 µg) measured in the same experiment. 
Bradford reagent    Serva Blue    100    mg 
      95% Ethanol (v/v)    50    ml 
      85% Phosphoric acid (v/v) 100    ml 
      H2O      up to 1l 
 
3.3.3 Western blot analysis (Immunoblotting) 
3.3.3.1 SDS-polyacrylamide gel electrophoresis of protein (SDS-PAGE) 
In SDS-PAGE the denatured polypeptides bind the strongly anionic detergent SDS and become 
negatively charged. The amount of SDS bound is always proportional to the molecular weight of 
the polypeptide and is independent of its sequence. This results in migration of SDS-polypeptide 
complexes through the polyacrylamide gel according to the size of the polypeptide. By using 
molecular weight markers, it is possible to estimate the molecular weight of the polypeptide 
chain(s). In most cases, SDS-PAGE is carried out with a discontinuous buffer system, in which 
the buffers in the reservoirs are of different pH and ionic strength from the buffers used to cast 
the gel. After migrating through a stacking gel of high porosity, the complexes are deposited in a 
very thin zone (or stack) on the surface of the resolving gel. The ability of discontinuous buffer 
systems to concentrate all the complexes in the sample into a very small volume greatly 
increases the resolution of SDS-polyacrylamide gels (Laemmli, 1970). 
100 µg of protein from the cell lysate was denatured by boiling at 95˚C for 5 min in 1 X loading 
buffer and cooled on ice immediately before loading on the corresponding polyacrylamide gel. 
The electrophoresis was performed at 10 mV/59 cm2 gel until the samples reached the 
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beginning of the resolving gel and the gel was subjected to 20 mA until the bromophenolblue 
dye had run out of the gel (for about 2 h). The size of the separated proteins was estimated in 
comparison to the standard protein marker mixture (Amersham) loaded on the gel. 
Preparation of SDS-PAGE gel  
     Resolving gel (10%)   Stacking gel (4%) 
Rotiphorese RGel30    2.33 ml    0.45 ml 
Resolving buffer (1.875 M Tris pH 8.8) 1.462   ml        - 
Stacking buffer  (0.6 M Tris pH 6.8)    -      0.27 ml 
Water      3.05 ml      1.9 ml 
10% SDS (w/v)       69     µl      27      µl 
10% APS (w/v)    34.5  µl      20 µl 
TEMED        2.2 µl        3 µl 
Running buffer (10X)    Tris (pH 8.3)     50 ml 
      Glycine    384 ml 
      SDS     0.1% (w/v) 
Loading buffer(4X)    Tris (pH 7.4)    100 mM 
      Bromophenolblue   0.05% (w/v) 
      SDS     3% (w/v) 
      Glycerol    7.5% (v/v) 
      DTT (Fresh)       5% (v/v) 
3.3.3.2 Electroblotting of immobilized proteins 
Resolved proteins on the SDS-PAGE were electronically transferred to a polyvinylidene fluoride 
(PVDF) membrane by electroblotting. The PVDF membrane was activated by methanol before 
transfer of the proteins onto it. The transfer equipment was prepared in the following way: a 
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whatmann 3 mm filter paper washed with anode buffer 1, on which two layers filter papers and 
the activated PVDF membrane washed with anode buffer 2 was placed into the electroblotting 
chamber. On the PVDF membrane, the gel and the other two layers of filter papers washed with 
cathode buffer were placed. The bubbles between the sheets were removed by gentle rolling of 
a glass pipette on top of the sandwich; the cathode plate was mounted and pressed with a 
weight approximately 1 kg for better contact between all layers. The transfer was performed with 
a constant electric current of 56 mA per gel for 1 h 20 min. The protein transfer was checked by 
reversible staining of the PVDF membrane with Ponceau S solution. 
Anode Buffer 1       Final concentration 
Tris (pH 11.3 with 2 M Borate)     36.4 g/l   300 mM 
Methanol      200 ml/l   20% (v/v) 
Anode buffer 2 
Tris (pH 10.6)             6 g/l                25 mM 
Methanol     200 ml/l   20% (v/v) 
Cathode buffer  
Tris (pH 9.0)             3 g/l               25 mM 
Methanol     200 ml/l   20% (v/v) 
Ponceau S        Final concentration 
Ponceau S         2.5  g/l              0.1%  (v/v) 
Glacial Acetic acid        150 ml/l              15%  (v/v) 
Methanol         400 ml/l               40%  (v/v) 
 
3.3.3.3 Immunological detection of proteins with specific antibodies 
The membrane with the protein was blocked with 5% non-fat milk in PBS at room temperature 
for 1 h followed by incubation with the primary antibody at 4 ˚C overnight. After washing with 1 X 
PBS + 0.1% Tween 20 for 3 X 10 min, the membrane was incubated with the respective 
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secondary antibody conjugated with horseradish peroxidase (HRP) in blocking buffer at room 
temperature for 1 h followed by 3 X 10 min washing. The HRP-conjugated secondary antibody 
was detected using ECL+ (Enhanced Chemiluminescence plus) kit (Amersham). The membrane 
was incubated with the enzyme substrate for 5 min at room temperature and the 
chemiluminescence was detected by exposing the membrane to X-ray film for an optimal time 




Co-immunoprecipitation is a technique to reveal protein-protein interactions. An antibody specific 
to the protein of interest is added to a cell extract. The antibody-protein complex is pulled down 
using protein G or A sepharose beads, which binds most of the antibodies. If there is any protein 
that interacts with the first protein, they will also be pulled down. Protein present in the pull down 
was identified by Western blot (if an antibody exists). 
HEK-293T cells transfected overnight and allowed for 24 h to overexpress the proteins which are 
expected to interact. Cells were washed twice with 1 X PBS and scraped with phospho-buffer 
and kept on a roller at 4 ˚C for 20 min. The cell lysate was centrifuged at 10 000 x g (12 000 
rpm, SS-34 rotor) for 15 min at 4 ˚C and the supernatant was collected into new tubes. The 
protein concentration of freshly isolated whole cell extract was determined by the Bradford 
method and 150 µg of protein was used for co-immunoprecipitation. 
Phospho-buffer        Final concentration 
5 X TBS     1  ml 
10 % Triton X-100            500  µl         1% (v/v) 
0.5 M EDTA                20 µl          2  mM  
0.5 M EGTA     20 µl          2  mM  
125 mM Na4P2O7            400  µl         10  mM 
PMSF (if necessary)    25 µl         0.2  M 
Deionized water     up to  5 ml 
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The buffer was made fresh before each preparation and 1 protease inhibitor tablet was used for 
10 ml of the buffer.   
Washing sepharose G beads 
Approximately 150 µl of the beads were washed twice with lysis buffer (without protease 
inhibitors). For each wash the beads were mixed gently in 1.5 ml of lysis buffer and centrifuged 
at 1000 x g (2500 rpm at a tabletop centrifuge Eppendorf, rotor 5415C) for 2 min. After the final 
wash the beads were resuspended in 500 µl of lysis buffer with protease inhibitors and ~110 µl 
of the beads were used for each pull down reaction.           
Pull down of protein-antibody complexes  
Two µg of antibody were added to the freshly isolated 150 µg whole cell extract and allowed to 
bind the target protein for 1 h at 4 ˚C on a roller. After 1 h, the samples were treated with washed 
beads and incubated overnight at 4 ˚C on a roller to pull down the interacting partner of the 
target protein (antibody-protein complexes). The protein-immune complexes bound to the beads 
were collected by centrifugation at 1000 x g (2500 rpm at a tabletop centrifuge Eppendorf, rotor 
5415C) for 2 min. The collected beads were washed 5 times with lysis buffer. Washed beads 
were resuspended with 2 X loading buffer, heated to 95 ˚C for 7 min and resolved by SDS-
PAGE for Western blot analysis.     
 
3.5 Enzyme activity assays 
To determine the glucokinase enzyme activity, primary rat hepatocytes were washed twice with 
0.9% NaCl and cells were scraped in the ice cold lysis buffer containing 100 mM Tris/HCl pH 
8.3, 150 mM KCl, 10 mM MgCl2, and 5 mM DTT. The cells were disrupted with ultrasound in a 
Polytron for 15 sec at half maximal settings consisting of ~230 V (50-60 Hz). The resulting 
suspension was then centrifuged at 16 000 x g (14 000 rpm at a tabletop centrifuge Eppendorf, 
rotor 5415C) for 30 min; the supernatant was collected into new tubes and stored at -70˚C. The 
protein content was determined using the Bradford method.  
The majority of enzyme activities can be determined as part of pyridine-dependent reactions in 
the simple optical assay or in the coupled optical assay. Glucokinase enzyme activity was 
determined by the coupled optical assay with glucose 6-phosphate dehydrogenase (G6PDH) 
and 6-phosphogluconate dehydrogenase (6PDGH). 
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Glucose                        +   ATP4-        GK  Glucose 6-phosphate2-  +  ADP3-  +  H+ 
Glucose 6-phosphate2- + NADP+    G6PDH              6-Phosphogluconate3-    + NADPH    +2H+ 
6-Phosphogluconate3-   +NADP+     6PGDH            Ribulose-5-phosphate2-   +   CO2  +  NADPH 
Fifty µg of total protein was mixed with the test solution described below along with different 
concentrations of glucose as substrate and water. The reaction mixture was mixed thoroughly; 
incubated at room temperature for 1 min and then, the change in extinction at 366 nm was 
measured. The reaction velocity (V) was calculated using the change in the extinction in 
dependence of the substrate concentration ([S]), from which the enzyme affinity (KM) and 
maximal velocity (Vmax) were determined. Glucokinase enzyme kinetics was represented 
graphically by Michaelis-Menten and Lineweaver-Burk plots. The Michaelis-Menten plot depicts 
the reaction velocity V versus ([S]), which gives a hyperbolic plot and the Lineweaver-Burk plot 
represents the double reciprocal of 1/V versus 1/ ([S]), which gives a straight-line. The Michaelis-
Menten plot is used to illustrate regulation problems and the Lineweaver-Burk straight lines gives 
fairly accurate determination of KM and Vmax. Plotting 1/V as a function of 1/ ([S]), the intercept on 
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Solutions for enzyme activity assay      Final concentration 
Glycylglycine buffer pH 7.5   13.2   g/l    100  mM 
Glucose            180.16    g/l        1  M 
ATP             0.2756   g/ 10 ml       50 mM 
MgCl2 X H2O            0.2033   g/ 10 ml      100 mM 
NADP+             0.0505   g/ 10 ml         6 mM 
Mercaptoethanol              3.52   µl/ 10 ml         5 mM  
G6PDH                    3   µl/ 10 ml     0.2 U/ ml 
6PGDH                100   µl/ 10 ml     0.2 U/ ml 
All the above solutions except glucose were made in glycylglycine buffer at pH 7.5. 
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Test solution       Final concentration 
Glycylglycine pH 7.5      100  mM/l 
ATP            5  mM/l 
MgCl2 X 6H2O           10  mM/l 
NADP+          0.6  mM/l 
Mercaptoethanol          5  mM/l 
G6PDH        0.2  U/ml 
6PGDH        0.2  U/ml 
 
Reaction mixture 
Cuvette 1 2 3 4 5 
 Amounts in µl 
Test solution 250 250 250 250 250 
Glucose 0.1 M/l 25 50 100 - - 
Glucose 1 M/l - - - 25 50 
Water Up to 500 µl 










4.1 Regulation of glucokinase gene expression by sterol regulatory element 
binding protein-1 (SREBP-1) 
 
Previous reports have shown that SREBP is involved in the regulation of glucokinase 
expression, however, the molecular details at the promoter level are not all known so far. Insulin 
can activate glucokinase gene expression via PI3K/PKB and it is known to induce SREBP gene 
expression. However, the role of insulin-induced SREBP mediated glucokinase gene expression 
is not well understood. By using Matinspector programme we have predicted three putative 
SREBP binding elements within a 1448 bp fragment of the rat glucokinase promoter. This 
prompted us to investigate the role of SREBP on glucokinase gene regulation. DNA footprinting 
assays identified seven elements bound by liver enriched factors on the rat liver glucokinase 
promoter, but the importance of these elements are not known. In order to understand the above 
questions we have made deletion constructs and different constructs carrying mutations in the 
putative SREBP binding sites as well as in the footprinted sites of the rat glucokinase promoter.   
 
4.1.1 Regulation of rat GK promoter deletion constructs by SREBP-1a     
 
Freshly isolated rat primary hepatocytes and HepG2 cells were used for cotransfection of 
glucokinase promoter deletion constructs with an expression vector for SREBP-1a. When 
primary rat hepatocytes or HepG2 cells were cotransfected with the GK promoter Luc constructs 
pGl3GK-1448, pGl3GK-919, pGl3GK-781 and the SREBP-1a expression vector, Luc activity was 
induced by SREBP-1a in the range of about 4-8-fold. By contrast, cotransfection of the SREBP-
1a expression vector did no longer enhance Luc activity when the pGl3GK-748 or pGl3GK-333 
promoter Luc constructs were cotransfected (Fig 13). These data suggest that the GK promoter 
region -781/-748 is important for SREBP mediated induction. Interestingly the sequence -781/-
748 includes footprint region B which may then be important for the SREBP effects. 
 
4.1.2 Mutation in the putative SRE-2 site abrogates the rat GK promoter activity by 
SREBP-1a 
 
Since the Matinspector programme proposed three putative SREBP binding elements namely 
SRE1 (-298/-290, 5’-ATCCCCCAC-3’), SRE2 (-204/-197, 5’-GTGGGGTG-3’) and SRE3 (-182/-
175, 5’- CCAGCCAC-3’), mutations were introduced by site-directed mutagenesis into these 
elements to generate pGl3GK-1448SRE1m, pGl3GK-1448SRE2m, pGl3GK-1448SRE3m and 
the constructs were then functionally tested in HepG2 cells and primary hepatocytes. HepG2 
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cells cotransfected with constructs carrying mutations in the SRE1 and SRE3 elements were 
able to show a 4-fold induction by SREBP-1a, however, a mutation in the SRE2 alone or in both 
SRE2+SRE3 as in the construct pGl3GK-1448mSRE2+mSRE3 abolished SREBP-1a mediated 
induction (Fig 14). By contrast, rat primary hepatocytes cotransfected with the pGl3GK-
1448SRE2m, pGl3GK-1448SRE3m or with the double mutant pGl3GK-1448mSRE2+mSRE3 
construct abolished the SREBP-1a induced Luc activity (Fig 14). These results indicate that both 
SRE2 and SRE3 are important for SREBP mediated activation in primary hepatocytes, whereas 
in HepG2 cells only SRE2 is involved in the SREBP mediated regulation of the rat GK promoter. 
 
4.1.3 Mutations in the B1 site abolished SREBP-1a-dependent GK promoter 
activity 
 
In-vitro DNA footprinting analysis of the rat glucokinase promoter revealed seven elements 
termed as A to G which were bound by liver enriched factors (Iynedjian et al., 1996). Serial 
deletions of the GK promoter eliminating footprint site G-D did not affect the SREBP-mediated 
GK promoter activity, but the SREBP effect was lost when the footprint B element was deleted 
(Fig 15). This prompted us to mutate the footprint site B in the full length GK promoter. We 
introduced two different mutations in the footprint region B to generate pGl3GK-1448mFPB1 and 
pGl3GK-1448mFPB2 as well as a construct carrying a double mutation pGl3GK-
1448dmFPB1+2. The glucokinase wild type promoter construct pGl3GK-1448 was induced by 
about 4-fold in both primary hepatocytes and HepG2 cells when cotransfected with the SREBP-
1a expression vector. Mutations in the footprint B1 and B1+2 abolished SREBP-mediated 
induction of Luc activity in primary hepatocytes. HepG2 cells cotransfected with pGl3GK-
1448mFPB2 showed an approximately 2-fold induction by SREBP. These data indicate that the 
footprint site B1 is most important for GK regulation by SREBP. Since SREBP can also bind to 
E-box sequences (5’-CANNTG-3’) we mutated the E-box sequence within the footprint site C. 
Transfection of the glucokinase construct pGl3GK-1448mE-box carrying the mutation in the 
footprint C site was induced by SREBP by about 3-fold in both cell types (Fig 15). These results 
further underline that the footprint site B1 is important in regulating the GK promoter activity in 












Figure 13. Activation of serially deleted GK promoter-Luc constructs by SREBP-1a in HepG2 cells 
and primary rat hepatocytes Primary rat hepatocytes and HepG2 cells were transiently cotransfected 
with the SREBP-1a expression vector and the GK-1448 wild type construct and deletion constructs GK-
919, GK-781, GK-748, and GK-333. After 5 h of transfection the medium was changed and cells were 
cultured for 48 hours. Black boxes A-G and P1&P2 in the GK promoter indicate foot-printed regions. White 
boxes indicate elements identified only by sequence similarity. In each experiment the percentage of Luc 
activity was determined to the GK-1448 control, which was set equal to 100%. The values represent 
means ± S.E. of three independent experiments. Statistics, Student’s t test for paired values: *, significant 






Figure 14. Activation of SRE mutated GK promoter-Luc constructs by SREBP-1a Primary rat 
hepatocytes and HepG2 cells were transiently cotransfected with the SREBP-1a expression vector and 
either a GK-1448 wild type construct, a 1448-bp construct mutated at SRE1 (GK-1448SRE1m), a 1448-bp 
construct mutated at SRE2 (GK-1448SRE2m), a 1448-bp construct mutated at SRE3 (GK-1448SRE3m) 
or a construct mutated at SRE2 and 3 (GK-1448mSRE2+mSRE3). After 5 h of transfection the medium 
was changed and the cells were cultured for 48 hours. In the GK promoter constructs the sequences in 
the upper strand represent the wild-type sequence. In the lower strand the mutant bases are indicated as 
lower case letters. In each experiment the percentage of Luc activity was determined to the GK-1448 
control, which was set equal to 100%. The values represent means ± S.E. of three independent 
experiments. Statistics, Student’s t test for paired values: *, significant differences control versus 
+SREBP-1a; p ≤ 0.05. 





Figure 15. Regulation of Footprint B and E-box mutated GK promoter-Luc constructs by SREBP-1a 
Primary rat hepatocytes and HepG2 cells were transiently cotransfected with the SREBP-1a expression 
vector and either a GK-1448 wild type construct, a 1448-bp construct mutated at E-box (GK-1448 mE-
box), a 1448-bp construct mutated at footprintB1 (GK-1448 mFPB1), a 1448-bp construct mutated at 
footprintB2 (GK-1448 mFPB2) or a construct mutated at footprintB1 and B2 (GK-1448 dmFPB1+2). After 
5 h of transfection the medium was changed and the cells were cultured for 48 hours. In the GK promoter 
constructs the sequences in the upper strand represent the wild-type sequence. In the lower strand the 
mutant bases are indicated as lower case letters. In each experiment the percentage of Luc activity was 
determined to the GK-1448 LUC control, which was set equal to 100%. The values represent means ± 
S.E. of three independent experiments. Statistics, Student’s t test for paired values: *, significant 
differences control versus +SREBP-1a; p ≤ 0.05. 
 
4.1.4 Reduction of SREBP-1a-dependent GK promoter activity by mutation of the 
HRE and HNF4 binding element 
 
Previously it was shown that the GK gene is regulated by insulin stimulated HIF-1 binding to the 
HRE together with binding of HNF4 to the HNF4 element in the GK promoter (Roth et al., 
2004a). It is known that SREBP-1 interacts with the AF2 domain of HNF-4 (Yamamoto et al., 
2004) and that HIF1β can interact with HNF4. This lead us to hypothesize that both the HNF4 
and HRE site could be critically involved in the SREBP-mediated GK gene expression. So we 
have used the GK promoter constructs carrying mutations in the HRE and HNF4 binding 
elements to study the SREBP mediated effects. Mutation in the HRE site (pGl3GK-1448HREm) 
reduced the SREBP-1-dependent GK promoter activity by about 2-fold in both HepG2 and 
hepatocytes. Mutation in the HNF4 site (pGl3GK-1448HNF4m) also reduced the SREBP-1-
dependent induction by about 2-fold in HepG2 cells whereas the induction by SREBP-1 was 
completely lost in primary hepatocytes. Cotransfection of the mutant pGl3GK-
1448HREm+HNF4m carrying mutations in both HRE and the HNF4 site showed a 2-fold 
induction as with the single mutants in both cell types (Fig 16). These results implicate that full 
induction of glucokinase gene expression by SREBP-1 requires these transcription factors. 




Figure 16. Regulation of HNF4 and HRE mutated GK promoter-Luc constructs by SREBP-1a 
Primary rat hepatocytes and HepG2 cells were transiently cotransfected with the SREBP-1a expression 
vector and either a GK-1448 LUC wild type construct, a 1448-bp construct mutated at HRE (GK-1448 
HREm), a 1448-bp construct mutated at the HNF-4 site (GK-1448 HNF4m), a 1448-bp construct mutated 
at the HRE and the HNF4 (GK-1448 HREm+HNF4m). After 5 h of transfection the medium was changed 
and the cells were cultured for 48 hours. In the GK promoter constructs the sequences in the upper strand 
represent the wild-type sequence. In the lower strand the mutant bases are indicated as lower case 
letters. In each experiment the percentage of Luc activity was determined to the GK-1448 control, which 
was set equal to 100%. The values represent means ± S.E. of three independent experiments. Statistics, 
Student’s t test for paired values: *, significant differences control versus +SREBP-1a; p ≤ 0.05. 
 
 
4.1.5 Induction of the FAS SRE enhancer Luc gene constructs by SREBP-1a 
 
To check whether the SREBP-1a expression system works in our cell culture, we have 
generated two SREBP control plasmids pGl3-4SRE Luc and pGl3-SR/SP Luc constructs 
harbouring consensus SREBP regulatory element (SRE) and/or a SP1 binding element (SPE) 
from the fatty acid synthase (FAS) gene. SPE was included since, SP1 transcription factor 
cooperate to the SREBP-1 to regulate gene expression FAS gene. The plasmid pGl3-4SRE Luc 
which consists of four SREs was induced by about 4-fold and the pGl3-SR/SP Luc construct 
which consists of three SREs and one SPE was induced by 14-fold when cotransfected with the 
SREBP-1a expression vector in rat primary hepatocytes. In HepG2 cells the construct containing 
four SREs was induced by about 6-fold and the construct containing three SREs and one SPE 
was induced about 2-fold when cotransfected with SREBP-1a (Fig 17). This shows that 








Figure 17. Activation of FAS SRE enhancer Luc gene constructs by SREBP-1a Primary rat 
hepatocytes were transiently cotransfected with the SREBP-1a expression vector and either a construct 
carrying three SREs and one SPE (pGL3-SRE/SPE LUC), a construct carrying four SREs (pGL3-4SRE 
LUC). After 5 h of transfection the medium was changed and the cells were cultured for 48 hours. The 
sequences shown in the above figure are the SREBP and SP1 sequences from the fatty acid synthase 
gene promoter. In each experiment the percentage of Luc activity was determined to the respective 
control plasmid, which was set equal to 100%. The values represent means ± S.E. of three independent 
experiments. Statistics, Student’s t test for paired values: *, significant differences control versus 
+SREBP-1a; p ≤ 0.05. 
 
 
4.1.6 Regulation of rat glucokinase gene expression by insulin, the LXR ligand TO-
901317 and by overexpression of SREBP-1a in primary rat hepatocytes 
 
Insulin is the major regulator of glucokinase in the liver (Roth et al., 2004a). Further, insulin is 
known to induce several other genes including the transcription factor SREBP. SREBP is 
thought to be a mediator of insulin effects; however, insulin-dependent SREBP-mediated 
glucokinase gene expression is still a mystery. TO-901317 is a LXR agonist which stimulates the 
gene expression of SREBP by binding to the LXR responsive elements present within the 
SREBP gene promoter. To demonstrate the modulation of glucokinase and SREBP gene 
expression by insulin and TO-901317, GK mRNA levels from rat primary hepatocytes were 
measured by northern blot analysis. Besides treating the hepatocytes with insulin and TO-
901317, primary hepatocytes were transfected with a SREBP-1a expression vector to measure 
the effects on glucokinase mRNA levels. 
Rat primary hepatocytes cultured for 24 h under standard conditions were treated with 10 µM 
TO-901316 for 16 h and challenged with 100 nM insulin for 1 h before the isolation of mRNA. 
When hepatocytes were stimulated with insulin alone for 1 h GK mRNA was induced by 4-fold 
and SREBP mRNA levels were induced by 8-fold (Fig 18 A). TO-901317 treatment alone for 16 
h increased GK mRNA by 4-fold and SREBP mRNA by nearly 35-fold (Fig 18 A). Insulin 
treatment for 16 h enhanced GK mRNA by 15-fold and SREBP mRNA induced by 30-fold (Fig 
18 A). Treatment of cells with TO-901317 for 16 h and insulin for 1 h did not show any additive 
effect on both the mRNA levels compared to the insulin-independent stimulation for 16 h (Fig 18 
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A). However, the mRNA levels of both genes were clearly enhanced when compared to the 1 h 
treatment with insulin alone. When hepatocytes were transfected with the SREBP-1a encoding 
vector the GK mRNA levels were increased by about 10-fold (Fig 18 A). These results indicate 
that besides insulin, SREBP alone can induce GK gene expression. Treatment with either TO-
901317 or insulin alone for 16 h strongly induced SREBP expression which in turn could activate 








Figure 18. Regulation of GK and SREBP mRNA expression levels by insulin and TO-901317 or by 
overexpression of SREBP in primary rat hepatocytes 
Freshly isolated hepatocytes were cultured 24 h under standard conditions. One sample was transfected 
with the SREBP-1a expression vector. At 24 h the medium was changed and cells were treated with 100 
nM insulin and 10 µM TO-901317 and cultured as indicated. A) The GK mRNA levels were measured by 
Northern blotting. The control mRNA level without insulin was set equal to 1. The values are from three 
independent culture experiments. B) Northern blot, 20 µg of total RNA prepared form the cultured 
hepatocytes were hybridized to digoxigenin labeled GK, SREBP-1 and β-actin antisense RNA probes. 
Autoradiographic signals were detected by chemiluminescence and densitometry was done using Image J 
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4.2 Regulation of rat liver glucokinase gene expression by FoxO transcription 
factors 
 
FoxO1 is the most abundant FoxO isoform in several insulin-responsive tissues such as liver, 
adipose tissue as well as pancreatic β−cells (Kitamura et al., 2005). FoxO transcription factors 
contribute to the regulation of cell growth and differentiation. Insulin via PKB/Akt-dependent 
phosphorylation of FoxO factors inhibits their transcriptional activity by nuclear exclusion. Earlier 
studies indicated that FoxO proteins bind to insulin responsive sequences (IRSs) in the target 
gene promoter. In addition to binding DNA target sites in target genes, FoxO proteins interact 
with and modulate the function of other transcription factors important for the regulation of gene 
expression in the liver. In contrast to insulin, transgenic mice expressing constitutively active 
FoxO1 showed stimulated gluconeogenic genes and suppressed expression of genes involved 
in glycolysis including glucokinase and SREBP (Zhang et al., 2006). However, the molecular 
mechanism of FoxO mediated suppression of glucokinase gene expression is not known yet. 
This led us to investigate the role of FoxO1-mediated suppression of glucokinase gene 
expression.  
 
4.2.1 Loss of FoxO1-mediated suppression of GK promoter activity by mutating 
the FBE b site     
 
Since the glucokinase gene can be down regulated by FoxO factors we looked for FoxO binding 
sites in the glucokinase promoter sequence and found two putative FoxO1 binding sites (5’ -558 
GTAAAACAA -550 3’ and 5’ -526 TTGTTTTAC -518 3’) separated by 21 bases. The 5’ 
sequence is designated as FoxO binding element a (FBEa) and the 3’ sequence is designated 
as FBEb. These putative binding sites were mutated by site directed mutagenesis to generate 
pGL3GK-1448mFBEa, pGL3GK-1448mFBEb and a double mutant pGL3GK-1448dmFBEab 
which were then functionally tested in primary hepatocytes and HepG2 cells. When primary rat 
hepatocytes and HepG2 cells were cotransfected with FoxO1 and GK-1448 containing in the 
wild type GK promoter Luc activity was reduced by about 7-fold in HepG2 cells; in hepatocytes 
the GK promoter activity was repressed by 4-fold (Fig 19). Since FoxO factors interact physically 
with HNF4 to regulate the gene expression (Hirota et al., 2003) we investigated the role of both 
transcription factors on GK promoter activity. Cotransfection of an HNF4 vector induced wild 
type GK promoter activity by about 2-fold in HepG2 cells and about 3-fold in hepatocytes (Fig 
19). The HNF4-mediated GK promoter induction was brought down in both cell types when 
FoxO1 was additionally cotransfected. Cotransfection of FoxO1 with the construct pGl3GK-
1448mFKHRa carrying a mutation in the putative FoxO1 binding site a did not abolish the 
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FoxO1-mediated repression as with the wild type GK promoter. The construct pGl3GK-
1448mFKHRb carrying a mutation in the putative FoxO1 binding site b or a construct pGl3GK-
1448dmFKHRab carrying mutations in both site a and b abolished the repression by FoxO1 in 
both cell types. Mutations in the FoxO1 sites increased the HNF4-dependent GK promoter 
activity in comparison to the wild type. However, HNF4-mediated induction was still inhibited in 
both cell types when FoxO1 and HNF4 were cotransfected together even when the repressive 
sites were mutated (Fig 19). These results indicate that repression activity of FoxO1 could be 
due to binding to the putative FoxO binding sites and interaction of FoxO1 with HNF4.      




Figure 19. Mutations in the putative FoxO binding elements lead to loss of FoxO1-mediated 
repression of GK promoter Luc constructs Primary rat hepatocytes and HepG2 cells were transiently 
cotransfected with the FoxO1 and/or HNF-4α expression vectors and either a GK-1448 wild type construct 
or a 1448bp construct mutated at the FBEa (GK-1448 mFBEa), the FBEb (GK-1448 mFBEb), and the 
FBEa and b (GK-1448 dm FBEab) sites. After 5 h of transfection the medium was changed and the cells 
were cultured for 48 hours. In each experiment the percentage of Luc activity was determined to the 
respective GK-1448 LUC control constructs, which were set equal to 100%. The values represent means 
± S.E. of three independent experiments. Statistics, Student's t test for paired values: * significant 
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4.2.2 Mutation in the HNF4 binding site leads to loss of FoxO1-mediated 
repression activity of GK promoter 
 
Even though mutations in the putative FoxO binding sites, the FoxO1 was able to reduce the 
HNF4-mediated induction of GK promoter activity. FoxO factors are known to interact physically 
with the DNA binding domain of HNF4. This led us to generate a mutation construct pGl3GK-
1448HNF4m containing a mutation in the HNF4 binding site of the GK promoter. Cotransfection 
of FoxO1 repressed the wild type promoter activity by about 6-fold in both cell types. HNF4 
induced GK promoter activity and the HNF4-mediated induction was inhibited by FoxO1 as in 
the previous experiment. Mutation of the HNF4 binding site lead to loss of FoxO1 influenced 
repression of the GK promoter either in the presence of FoxO1 alone or together with HNF4 (Fig 
20). These results indicate that FoxO1 can repress GK promoter activity via interaction with 




Figure 20. Mutation of the HNF4 binding element leads to loss of FoxO-1-mediated repression of 
GK promoter Luc constructs Primary rat hepatocytes and HepG2 cells were transiently cotransfected 
with the FoxO1 and/or HNF4 expression vectors and either a GK-1448 wild type construct or a 1448bp 
construct mutated at the HNF4 site (GK-1448 HNF4m). After 5 h of transfection the medium was changed 
and the cells were cultured for 48 hours. In each experiment the percentage of Luc activity was 
determined to the GK-1448 wild type and HNF4m LUC control constructs, which were set equal to 100%. 
The values represent means ± S.E. of three independent experiments. Statistics, Student's t test for 
paired values: * significant differences control versus FoxO1 or versus HNF4α, or versus FoxO1+HNF4α; 
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4.2.3 Regulation of glucokinase mRNA levels by insulin, glucagon and cAMP 
 
Insulin and glucagon act antagonistically on many genes involved in glucose metabolism. GK 
mRNA levels were induced in primary rat hepatocytes treated with 100 nM insulin for 5 h, and 
repressed when hepatocytes were treated with 10 nM glucagon and 100 µM cAMP for 5 h. In 
contrast, the mRNA of the gluconeogenic gene PEPCK was induced by glucagon and cAMP and 
inhibited by insulin (Fig 21 A).         
During fasting stages glucagon levels are high and inhibit many of the genes involved in 
glycolysis and induce the genes involved in gluconeogenesis to maintain normal blood glucose 
levels. When Male Wistar rats were fasted for 48 h the protein levels of glucokinase were 
completely undetectable, however, the GK protein levels become, again visible after a refeeding 
period of 2 h (Fig 21 B) since during refed stages insulin levels are high and regulate the blood 
glucose levels by inducing genes involved in the glucose metabolism such as glucokinase. 
Glucagon signaling is known to activate FoxO gene transcription by inhibiting the PKB pathway, 
which will regulate the target genes (Kuiperij et al., 2005). In normal fed rats the protein levels of 
FoxO1 were less in comparison to the 48 h fasted rat and 48 h fasted and 2 h refed rat. These 
results explain that, FoxO1 could be a downstream target of glucagon signaling. FoxO1 
suppresses the glycolytic gene glucokinase and activates gluconeogenic genes like PEPCK 
during fasting to maintain glucose homeostasis (Fig 21). In conclusion FoxO factors could be 
one of the key players in carbohydrate metabolism. 
A)                                                                       B)  
 
    
 
Figure 21. Insulin and glucagon/cAMP act antagonistic on GK and PEPCK transcription and 
regulation of GK during fasting and refeeding A) Freshly isolated primary rat hepatocytes were 
cultured for 5 h in basal medium M199 containing 0.5 nM insulin, 100 nM dexamethasone and 4% fetal 
calf serum (FCS). After 5 h cells were cultured for 19 h without insulin and FCS. After 19 h the cells were 
incubated with 100 nM insulin, 10 nM glucagon and 100 µM cAMP for 5 h. After 5 h of treatment, total 
RNA was isolated and 20 µg of RNA subjected to Northern analysis with respective digoxigenin-labeled 
anitsense RNA probes. Autoradiographic signals were obtained by chemiluminescence. B) Male Wistar 
rats housed in controlled environmental conditions were used for fasting and refeeding experiment. 
Protein isolated from the frozen liver was used to examine the liver glucokinase and FoxO1 protein levels. 
Golgi membrane (GM) antibody was used as loading control.    
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4.2.4 Modulation of rat liver glucokinase promoter by resveratrol 
Resveratrol is a phytoalexin abundantly present in a plant Polygonum capsidatum and skin of 
red grapes. It is supposed that resveratrol has a number of beneficial health effects against 
cancer, aging, inflammation and diabetes. Resveratrol is known to increase the activity of the 
enzyme SIRT1 (sirtuins) which deacetylates the endogenous inactive FoxO to active FoxO. 
Since the previous results indicated that the glucokinase promoter is suppressed by 
overexpressed FoxO1 we wanted to prove the effect of endogenous FoxO on the glucokinase 
promoter by stimulating hepatocytes with resveratrol. Primary rat hepatocytes were transfected 
with the GK wild type and the constructs carrying mutations in the FoxO binding sites and the 
HNF4 binding site and treated with 50 µM resveratrol for 24 h before measuring Luc activity. 
Wild type GK promoter activity was reduced by 3-fold and the construct pGl3GK-1448mFBEa 
carrying a mutation in the FBEa site was suppressed by 2-fold when treated with resveratrol. 
The hepatocytes transfected with the construct pGl3GK-1448mFBEb carrying a mutation in the 
FBEb site or the construct pGl3GK-1448HNF4m a carrying mutation in the HNF4 binding site or 
the construct pGl3GK-1448mFBEab carrying mutations in both FoxO binding sites showed no 
reduction in Luc activity when treated with 50 µM resveratrol (Fig 22). These results indicate that 
mutations in the FoxO binding sites or in the HNF4 binding site leads to a loss of resveratrol 














Figure 22. Mutations in the FoxO binding elements lead to loss of resveratrol mediated repression 
of GK promoter Luc constructs Primary rat hepatocytes were transiently transfected with either a GK-
1448 wild type construct or a 1448bp construct mutated at the FBEa (GK-1448 mFBEa), the FBEb (GK-
1448 mFBEb), and the FBEa and b (GK-1448 dm FBEab) sites a 1448bp construct mutated at the HNF4 
site (GK-1448 mHNF4). After 5 h of transfection the medium was changed and the cells were cultured for 
24 h and the medium was changed again and stimulated the hepatocytes with 50 µM resveratrol for 24 h. 
In each experiment the percentage of Luc activity was determined to the respective GK-LUC control 
constructs, which were set equal to 100%. The values represent means ± S.E. of three independent 
experiments. Statistics, Student's t test for paired values: * significant differences control versus 
resveratrol 50 µM; p ≤ 0.05. 
 
 
4.2.5 In-vivo binding of FoxO1 with HNF4 in HEK293T cells 
 
Since HNF4-mediated glucokinase promoter activity was repressed by FoxO1 in luciferase 
assays, we intended to determine the physical interaction of FoxO1 with HNF4 by co-
immunoprecipitation. HEK293T cells were transiently transfected with Flag-tagged FoxO1 
expression vector along with HNF4 expression vectors. Approximately 200 µg of cell lysate was 
immunoprecipitated with anti-HNF4 antibody and the immune complexes were resolved by SDS-
PAGE, followed by Western blotting with antibodies against FoxO1 and HNF4. The HNF4-
precipitated complexes include FoxO1 (Fig 23), demonstrating the in vivo interaction between 
FoxO1 and HNF4. Foxo1 and HNF4 over expressed lysates were used as positive controls and 
were immunoblotted using anti-FoxO1 antibody and anti-HNF4 antibody, anti-Golgi membrane 









Figure 23. Interaction of FoxO1 with HNF4 in HEK293T cells HEK 293T whole cell extracts that 
expressed Flag-tagged FoxO1 along with full length HNF4 were used for in vivo binding. FoxO1 was 
immunoprecipitated using anti-HNF4 antibody. Whole cell extracts (WCE) and immunoprecipitated 
complexes were resolved on SDS-PAGE and immunoblotted with anti-FoxO1 antibody HNF-4 and GM 
antibodies.  
 
4.2.6 Modulation of FoxO1-mediated repression of the GK promoter by insulin  
Insulin signalling via the PI3K/PKB pathway induces glucokinase gene expression and has a 
dynamic effect on FoxO factors due to phosphorylation of FoxOs by PKB. This prompted us to 
investigate the effects of insulin on the repressive activity of FoxO1 on the GK promoter. 
Hepatocytes transfected with the wild type GK promoter construct (pGl3GK-1448) were induced 
by about 2-fold when stimulated with 100 nM insulin alone (Fig 24). The GK promoter activity 
was reduced by 2-fold when FoxO1 was cotransfected, however, the repressive activity of 
FoxO1 was completely abolished in the presence of insulin and the GK promoter activity 
regained an induction of 2-fold as with insulin alone (Fig 24). These results demonstrate that 
insulin signalling dominates and inactivates FoxO1, which leads to a loss of GK repression. 
















Figure 24. Insulin abolished the FoxO1-mediated repression of GK promoter Luc constructs 
Primary rat hepatocytes were transiently cotransfected with FoxO1 along with GK-1448 wild type 
construct. After 5 h of transfection the medium was changed and the cells were cultured for 24 h. After 24 
h the medium was changed again and stimulated with 100 nM insulin for further 20 h. In each experiment 
the percentage of Luc activity was determined to the respective GK- LUC control construct, which was set 
equal to 100%. The values represent means ± S.E. of three independent experiments. Statistics, 
Student's t test for paired values: * significant differences control versus insulin 20 h, or versus FoxO1, or 
versus FoxO1+insulin 20 h; p ≤ 0.05. 
 
 
4.2.7 Resveratrol inhibits insulin-induced glucokinase mRNA and protein levels 
 
Since resveratrol repressed the glucokinase promoter we investigated the effects of resveratrol 
also on GK mRNA and protein levels. Resveratrol is known to activate the deacetylating enzyme 
SIRT1 which in turn activates FoxO factors by deacetylation (Daitoku et al., 2004). Primary rat 
hepatocytes were treated with 10 µM and 50 µM resveratrol for 2 h and challenged with 100 nM 
of insulin for another 16 h. While resveratrol at 10 µM initiated a minor reduction of GK mRNA, 
resveratrol at 50 µM reduced GK mRNA expression below basal. In hepatocytes treated with 10 
µM resveratrol for 2 h and then challenged with 100 nM insulin, the inhibitory effect of resveratrol 
on GK mRNA was lost and insulin induced GK expression, showing that insulin signalling 
dominated the resveratrol mediated repression. Treatment of hepatocytes with insulin and 50 
µM resveratrol did not show a derepression of GK mRNA (Fig 25 A). In contrast to GK 
expression, resveratrol alone induced PEPCK mRNA levels. Further, the inhibitory effect of 
insulin on PEPCK gene expression was reversed by resveratrol at 50 µM but not at 10 µM (Fig 
25 A).  
The effect of resveratrol on insulin induced glucokinase gene regulation was also examined at 
the protein level. In order to visualize the GK protein on Western analysis the hepatocytes were 
stimulated with 250 nM of insulin. Hepatocytes treated with 10 µM resveratrol did not show any 
inhibitory effect on GK protein when compared to control (Fig 25 B). However, resveratrol alone 
at 50 µM or even in the presence of insulin reduced GK protein levels below the detection limit, 
showing that resveratrol inhibits insulin-mediated effects and represses the GK protein. Insulin 
alone induced GK protein levels when compared to control cells (Fig 25 B). These results 
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conclude that resveratrol acts against to insulin signalling and blocks the insulin mediated effects 
on glucokinase both at mRNA and protein levels. Resveratrol mediated repression on GK gene 
expression could be via activating the FoxO transcription factors by deacetylation. 
 
        A)                     B)   
 
 
Figure 25. Regulation of GK and PEPCK gene expression by insulin and resveratrol in primary rat 
hepatocytes  
Freshly isolated hepatocytes were cultured 24 h under standard conditions. A 24 h the medium was 
changed and cells were treated with 100 nM insulin and 10 µM and 50 µM resveratrol respectively and 
cultured for further 16 h. A) Northern blot, 20 µg of total RNA prepared form the cultured hepatocytes were 
hybridized to digoxigenin labeled GK, PEPCK and β-actin antisense RNA probes. Autoradiographic 
signals were detected by chemiluminescence. B) Western blot, hepatocytes were cultured for 24 h and at 
24 h the medium was changed and cells were stimulated with insulin and resveratrol. A total of 100 g of 
protein from the hepatocytes were subjected to Western analyses with an antibody against glucokinase, 




4.2.8 Down regulation of glucokinase gene expression by FoxO1 and SIRT1 
overexpression  
 
Our previous results on GK promoter down regulation by FoxO1 and resveratrol prompted us to 
prove the effects of FoxO1 and its upstream deacetylase SIRT1 on glucokinase mRNA levels. In 
hepatocytes transfected with an expression vector coding for FoxO1, the GK mRNA levels were 
reduced when compared to control cells (Fig 26 A). Likewise, hepatocytes transfected with the 
SIRT1 expression vector showed down regulation of GK mRNA as in the FoxO1 transfected 
cells (Fig 26 A). These results suggest that FoxO1 can be a downstream target of SIRT1 and is 
involved in the down regulation of glucokinase gene expression. In order to check the 
overexpression of FoxO1 and Myc-tagged SIRT1, HEK293T cell lysates were analysed by 
Western Blot to detect FoxO1 by anti-FoxO1 or SIRT1 by anti-Myc tag antibody, the Golgi 
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      A)                   B)   
 
 
Figure 26. Regulation of GK and PEPCK gene expression by FoxO1 and SIRT1 in primary rat 
hepatocytes 
Freshly hepatocytes were transfected with FoxO1 and SIRT1 expression vectors and after 5 h of 
transfection the medium was changed and cultured for 24 h. After 24 h the medium was changed again 
and cultured for further 24 h. A) Northern blot, 20 µg of total RNA prepared form the cultured hepatocytes 
were hybridized to digoxigenin labeled GK, PEPCK and β-actin antisense RNA probes. Autoradiographic 
signals were detected by chemiluminescence. B) Western blot, cells were transfected with FoxO1 and Myc 
tagged SIRT1 expression vectors and cultured for 24 h. Total cell extracts were isolated from the cells and 
used to detect the expression levels of FoxO1 and SIRT1. A total of 100 µg of protein was subjected to 
Western analyses with an antibody against Myc-tag or FoxO1 or Golgi membrane. Autoradiographic 




4.2.9 Resveratrol deacetylated p300-dependent acetylated FoxO1 
 
Resveratrol is known to activate SIRT1 which possess deacetylating activity. Since resveratrol 
showed repression GK expression we examined whether resveratrol can mediate deacetylation 
of FoxO1. To study the effects of resveratrol on deacetylation of FoxO1 we have used p300 
possessing acetylating activity. The transcriptional co-activator p300 possesses histone 
acetyltransferase activity and plays an important role in activation of gene expression. Thus, 
p300 binds and acetylates FoxO1 at K242, K245, and K262 which leads to attenuation of FoxO1 
as a transcription factor (Fukuoka et al., 2003). Therefore, we cotransfected HEK293T cells with 
Flag-tagged FoxO1 and p300 expression vectors and treated the samples with resveratrol. To 
identify the acetylation status of FoxO1 we have used an antibody which specifically detects the 
K242 and K245 residues of FoxO1. Cells transfected with FoxO1 alone did not show any 
acetylation, whereas cells transfected with FoxO1 together with p300 showed acetylation of 
FoxO1, which indicates that FoxO1 is acetylated by p300. However, p300 acetylated FoxO1 was 
deacetylated by 50 µM resveratrol in 6 h (Fig 27). These results support our previous results that 
inactive FoxO1 is activated by resveratrol by deacetylation which in turn represses the 
glucokinase gene expression.        
 




Figure 27. Resveratrol deacetylates p300 acetylated FoxO1  
HEK293T cells transfected with expression vectors of Flag-tagged FoxO1 and p300 were cultured for 24 
h. One sample was treated with 50 µM resveratrol for 6 h as indicated. 150 µg of whole cell extracts from 
the HEK293T cells were resolved by SDS-PAGE. The anti-acetylated FoxO1 (K242/245) antibody 
specifically recognizing the acetylated K242 and K245 residues in Foxo1 was used to detect acetylated 
FoxO1. The p300 was detected using anti-p300 antibody and Flag-tagged FoxO1 was detected with anti-
Flag antibody. Golgi membrane antibody was used as loading control. Autoradiographic signals were 
obtained by chemiluminescence. 
 
4.2.10 Repression of glucokinase enzyme activity by resveratrol and FoxO1 in 
primary rat hepatocytes 
 
The previous results showed down regulation of glucokinase gene expression by resveratrol and 
this could be reversed by insulin at both mRNA and protein levels. To support the previous data, 
we aimed to study the effect of resveratrol on GK enzyme activity which was measured in 
primary rat hepatocytes. Whole cell extracts were used for qualitative analysis of the glucokinase 
enzyme activity by Michaelis-Menten and Lineweaver-Burk methods. The rate of the reaction 
and the Vmax was calculated by Michaelis-Menten method and linearization of Michaelis-
Menten curves will give the Lineweaver-Burk plot which explains the Km and glucokinase Km 
falls between 8 -16 mM. Hepatocytes were treated with different concentrations of resveratrol 
alone and some samples treated with resveratrol were challenged with 250 nM insulin. The GK 
enzyme activity was measured in the presence of different glucose concentrations and it was 
found that it was not affected by resveratrol alone at 10 µM. However, when 10 µM resveratrol 
treated cells were challenged with 250 nM insulin, the Vmax of the GK enzyme activity was 
reduced compared to the insulin treated control although it was induced compared to the 
untreated control GK (Fig 25 & 28 C). By contrast, the enzyme activity was suppressed by 50 
µM resveratrol alone and this was not reversed by insulin. Insulin alone induced the rate of the 
reaction and Vmax of GK enzyme activity, as observed at mRNA and protein levels (Fig 25 & 28 
A and C). Linearization of the Michaelis-Menten curves gives the Lineweaver-Burk plots of GK 
enzyme activity for different treatments. The intercept of lines on the negative X-axis gives the 
Km, treatments with resveratrol and insulin did not change the Km of glucokinase which falls 
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between -0.06 to -0.1 i.e 10-15 mM of glucose (Fig 28 C). This explains that the velocity of the 
glucokinase enzyme activity was due to the reduced amount of the enzyme.  
Hepatocytes were then transfected with a constitutively active FoxO1 to prove that FoxO1-
mediated suppression of glucokinase is visible also at the enzyme activity. Hepatocytes 
transfected with constitutively active FoxO1 displayed significantly reduced Vmax of glucokinase 
(Fig 28 F). The Km values for control and FoxO1 were between -0.06 to -0.1 which is equal to 
10-15 mM glucose (Fig 28 E). These results indicate that FoxO1 is a major modulator for the 


































Figure 28. Regulation of glucokinase enzyme activity by resveratrol and FoxO1 in primary rat 
hepatocytes Freshly isolated hepatocytes were cultured 24 h under standard conditions. After 24 h the 
cells were given fresh medium and stimulated with Resveratrol and insulin (250 nM) for further 20 h as 
indicated in the panels A, B and C. Hepatocytes were transfected with constitutively active FoxO1 to 
measure the GK enzyme activity as showed in the panels D, E, and F. Panel A, B, D and E are the 
qualitative analysis of glucokinase enzyme activity measured by Michelis-Menten and Lineweaver-Burk 
plots and are made from the average of three independent experiments. Panel C and F depicts the Vmax 
of the glucokinase enzyme activity calculated from three independent experiments. In each experiment the 
percentage of Vmax was determined to the control, which was set equal to 100 %. The R2 values for the 
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5. Discussion 
Glucose is the major nutrient carbohydrate which can be utilized in mammals by all cells to 
produce energy in the form of adenosine triphosphate (ATP). Once glucose enters into the cells 
through specific glucose transporters (GLUTs) the first step of glucose utilization is 
phosphorylation of glucose to glucose 6-phosphate. This can be done by four different 
hexokinases I - IV from which hexokinase IV is termed glucokinase (GK). Glucokinase acts as a 
glucose sensor in pancreatic β-cells and in hepatocytes to maintain glucose homeostasis. 
Mutations in the GK gene cause Maturity Onset Diabetes of the Young Type II (MODY II). GK is 
encoded by a single gene consisting of 10 exons; it has two widely separated and functionally 
distinct cell-type specific promoters. The upstream promoter is operating in pancreatic β-cells 
whereas the downstream promoter is responsible for hepatic GK gene transcription. In the liver, 
GK expression is regulated in response to fasting and refeeding (Iynedjian et al., 1989) with 
insulin and glucagon acting as the major regulators. Hepatic GK gene expression is mainly 
stimulated by insulin in the less aerobic perivenous zone of the liver by both HIF-1 and HNF-4 
(Roth et al., 2004a). In addition to HIF-1 and HNF4, insulin regulates several other transcription 
factors including forkhead transcription factors (FOXO), activator protein-1 (AP-1) and sterol 
regulator element binding protein (SREBP). Insulin and glucose have been well known to 
stimulate lipogenesis through induction of SREBP-1 expression, which is highly nutritionally 
regulated in the liver and adipose tissues (Matsuzaka et al., 2004) and SREBP-2 involved in 
regulating genes involved in cholesterol synthesis. SREBP-1 was shown to be important as a 
dominant negative form of SREBP-1 inhibited the insulin-dependent GK gene expression (Foretz 
et al., 1999b) and transfection of SREBP-1a enhanced GK promoter activity (Roth et al., 2004a). 
Even though SREBP-1 activates GK gene expression, there are discrepancies in the 
understanding the effects of insulin-mediated SREBP-1 regulation of GK expression. FoxO 
transcription factors belong to the fork head family of transcription factors which can also 
participate in the regulation of genes involved in glycolysis and gluconeogenesis. FoxO factors 
are dynamically regulated by insulin signaling, since phosphorylation of FoxO factors by PKB 
leads to nuclear exclusion. Glucagon stimulates the FoxO gene expression to induce the genes 
involved in gluconeogenesis. Recent reports on transgenic mice expressing constitutively active 
FoxO1 in the liver showed negative regulation of glucokinase gene expression (Zhang et al., 
2006). However, molecular details of this negative regulation of FoxO1 on glucokinase gene 
expression are still not known to the last detail. The present study has shown that both insulin 
and SREBP-1 induced GK gene expression individually in primary rat hepatocytes. Insulin 
signaling activated SREBP-1 gene transcription within 16 h which could in turn activate the GK 
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gene expression in a cooperative manner. A GK promoter characterization with transfection 
assays revealed that putative SREBP binding elements 2 and 3 of the GK promoter appear to be 
important for the SREBP-1 effect. In addition it was found that deletion or mutations in the foot 
print region B lead to loss of promoter regulation by SREBP-1 even though the nucleotide 
sequence of the site does not resemble a classical SREBP binding site. So far, the factor 
binding to the foot print B site is unknown.    
Investigation of the negative GK expression by FoxO1 revealed that FoxO1 could mediate its 
effect via the putative FoxO1 binding sites present in the GK promoter or via interacting with 
HNF-4. During fasting stages glucagon signaling might activate FoxO1 at the gene level or it 
could be deacetylated by SIRT1 proteins. This would promote the nuclear localization of FoxO 
which then can induce the gluconeogenic genes such as PEPCK and repress the genes 
involved in glycolysis like glucokinase.   
 
5.1 Regulation of glucokinase expression by insulin and SREBP-1a 
5.1.1 Transcriptional regulation of glucokinase and SREBP-1 by insulin 
The pancreatic hormone insulin acts on primary target tissues including muscle, adipose tissue, 
and liver. Insulin is known to regulate many genes involved in many processes including energy 
metabolism. Insulin induces transcription of genes encoding glycolytic enzymes and down 
regulates genes encoding gluconeogenic enzymes by modulating several transcription factors 
such as SREBP-1. A key liver enzyme that is transcriptionally induced by insulin in hepatocytes 
is glucokinase and the insulin-dependent maintenance of glucokinase activity is essential for the 
liver to maintain glucose homeostasis when carbohydrate supply is high. SREBP-1 is known to 
activate genes involved in glycolytic and lipogenic pathways which lead to the synthesis of fatty 
acyl-CoA from glucose carbon atoms for lipid storage. Previous evidence suggests that the 
insulin-dependent induction of liver GK transcription could be mediated by SREBP-1, which itself 
is induced at the transcriptional level by insulin in the liver (Foretz et al., 1999a). In this study, 
treatment of hepatocytes with insulin for 1 h induced SREBP-1 mRNA to values which were 2-
fold higher than the GK mRNA levels. Treatment of insulin for 16 h induced SREBP-1 mRNA 10 
fold more than GK mRNA. Treatment of hepatocytes with the LXR ligand (TO-901317) at 10 µM 
for 16 h showed tremendous enhancement of SREBP-1 mRNA. However, the effect of TO-
901317 on the GK was similar to the effect of insulin after 1 h. LXR ligand stimulated 
hepatocytes did not show any additive effect on the transcription of both genes. Transfection of 
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hepatocytes with SREBP-1 showed a similar effect as insulin on GK mRNA expression (Fig 18). 
These results could explain that during a high carbohydrate diet, insulin induces GK gene 
expression as an early response to store the increased glucose as glycogen. However, long 
term regulation could be via insulin induced SREBP-1 since the excess glucose can then be 
stored as fat by activating the lipogenic pathway.  
 
5.2 Regulation of glucokinase promoter activity by SREBP-1a 
5.2.1 The B site in the GK promoter is important for the SREBP-1a-mediated 
induction 
Previous studies showed that SREBP-1a induced the GK promoter (Roth et al., 2004a); however 
the molecular details were not known about the SREBP-1a-dependent regulation of the GK 
promoter. In the present study we have used a -1448 bp fragment of the liver specific rat GK 
promoter to understand its regulation by SREBP-1a. Computational analysis of -1448 bp 
fragment predicted three putative SREBP binding elements. DNaseI footprint analysis of the GK 
promoter detected seven elements A-G (in 3’ to 5’ direction) specifically interacting with liver 
enriched factors. The 3’ end of the promoter contains additional footprints P1 and P2. The P1 
element was shown to be involved in binding of HNF-4 (Roth et al., 2002). The element P2 has 
been shown to be bound by USF-1, USF-2 (Iynedjian, 1998) as well as HIF-1 (Roth et al., 
2004b). A deletion analysis showed that P1 and P2, although P2 contains an E-box sequence 
which can theoretically be bound by SREBP, are not involved in the SREBP effect (Roth et al., 
2004a). However, the importance of the footprints A-G in SREBP-1a mediated regulation was 
not studied yet. The present study showed that a serial deletion of the GK promoter up to -781 
which excludes the footprints from C to G did not affect the SREBP-1a-mediated induction. In 
line, sequence analysis of the Footprint C of the GK promoter predicted a typical E-box 
(CANNTG) which could be bound by SREBP1. Mutation of this E-box element did not abolish 
the SREBP-1a-mediated GK promoter activity. Interestingly, deletion of the GK promoter further 
to -748 which omits the footprint B abolished the SREBP-1a-mediated activation even though 
three other putative SREBP binding sites not located in footprinted areas remained intact. The 
deletion studies showed for the first time that footprint B appears to be important for the SREBP-
1a mediated regulation of the GK promoter. Since the B site can be divided in two parts we 
aimed next to understand the contribution of each part of the B site for the SREBP-1-dependent 
induction. Therefore we generated the constructs GK-1448mFPB1 and GK-1448mFPB2, 
respectively. Site-directed mutation of the footprint B1 completely abolished the GK promoter 
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activity by SREBP-1a in primary hepatocytes and HepG2 cells. Interestingly, sequence analysis 
of the footprint B1 and B2 revealed that this site does not match to any known SREBP binding 
site. Thus, it could be the so far unknown liver enriched factor which could be important for the 
SREBP-1-mediated induction of the GK promoter in the liver.             
 
5.2.2 The SRE2 and SRE3 elements are important for the SREBP-1a-mediated 
induction of the GK promoter 
In the current investigation, the wild type GK promoter (GK-1448) was induced when 
cotransfected with SREBP-1a in both primary rat hepatocytes and HepG2 cells. Site-directed 
mutagenesis of the computer predicted putative SREBP binding elements SRE2 and SRE3, 
revealed that SREBP-1a-dependent induction was unchanged when the SRE3 element was 
mutated whereas loss of SRE2 abolished induction in HepG2 cells (Fig 14). Transient 
transfection assays showed that both SRE2 and SRE3 were necessary for the transactivation of 
GK promoter by SREBP-1a in primary hepatocytes. The differential regulation of GK promoter 
by SREBP-1 in different cell types could be utilization of SRE2 and SRE3 elements in a different 
manner or it could be some other factors involved. Previous investigations suggested that the 
binding of SREBP-1 to SRE2 or SRE3 was not mutually exclusive since SRE2 showed stronger 
affinity to SREBP-1 than SRE3, in contrast transient transfection in Alexander cells showed that 
both SRE2 and SRE3 were necessary for the transactivation of GK by SREBP-1c. In parallel, 
Chip analysis of high carbohydrate diet induced SREBP-1 showed binding with the liver GK 
promoter (Kim et al., 2004). With the current knowledge it is difficult to explain the relationship 
between SRE2 and SRE3 by insulin-dependent SREBP-1-mediated activation of liver GK.  
 
5.2.3 Co-operativity of HNF-4 and SREBP-1a is important for the regulation of the 
GK promoter  
The hepatocyte nuclear factor-4α (HNF-4) and SREBP-1 have been shown to be important for 
many genes involved in glucose metabolism (Yamamoto et al., 2004). Previous studies showed 
that HIF-1α, HNF-4 and p300 function co-operatively to enhance the activity of the liver-specific 
GK promoter (Roth et al., 2004a). The present investigation showed that mutations in the HNF-4 
binding site of the GK promoter attenuated the SREBP-1a-dependent activation of the promoter 
in primary rat hepatocytes (Fig 16) whereas mutations in the HRE site were unable to abolish 
the SREBP-1a effect. This was at the first glance unexpected but a possible explanation could 
be that all these factors are co-operatively involved in the regulation of GK expression. This 
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appears to be possible since insulin does not only activate SREBP expression but also 
phosphorylation of the coactivator p300 via PKB signaling. This coactivatior was shown to 
interact with both SREBP (Giandomenico et al., 2003) and HNF4 (Roth et al., 2004a). Thus, 
mutation of the HNF4 site may then abolish the interaction of HNF4 and p300 together with 
SREBP. However, under hypoxic conditions the SREBP may be replaced by HIF-1. This would 
allow the cell to have a redundant system which can adapt to different environmental conditions.      
   
 
 
Figure 29. Insulin-dependent SREBP-1a-mediated regulation of glucokinase gene expression 
Insulin activates both SREBP-1 and glucokinase gene expression via the PI3K/PKB pathway. GK gene 
expression could be activated by both insulin signaling as well as by insulin activated SREBP-1. The 
nuclear receptors LXRα are known to be activated by oxysterols or synthetic nonsteroidal LXR agonist 
TO-901317. Thus activated LXRα induce the SREBP-1 gene expression which is involved in the 
regulation of several genes involved in the lipogenesis besides glucose metabolism. When hepatocytes 
are stimulated with the insulin, SREBP-1 gene expression becomes activated which in turn activate GK 
gene expression in an insulin independent manner. Thus activated GK would convert glucose to glucose 
6-phosphate which could augment the glycogen levels and in the presence of excess glucose, it could be 
shuttled to the lipogenic pathway.  
Insulin receptor substrates (IRS); phosphoinositide 3-kinase (PI3K); phosphatidylinositol phosphate-
dependent kinase-1 (PDK-1); protein kinase B (PKB); Glucose transporter 2 (Glut2); Liver x receptor 
(LXR); Glucose 6-phosphate (G6-P); Glucokinase (GK);  
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5.3 Down regulation of glucokinase gene expression by the transcription factor 
FoxO1 
In this investigation, we found that the GK gene expression was suppressed by FoxO1. This 
appeared to be due to the direct action of FoxO1 alone and via its interaction with HNF-4α in 
both primary rat hepatocytes as well as in HepG2 cells. To our knowledge these studies provide 
first time evidence that liver specific GK gene expression is down regulated by FoxO1 by these 
two mechanisms.  
It is well known that liver-specific GK promoter activity can be induced by HNF-4α (Roth et al., 
2004a). FoxO1 is a major transcription factor involved in the activation of genes involved in the 
production of glucose. Recent reports on FoxO1 showed that they are involved in the down 
regulation of genes regulating the induction of glucose output (Zhang et al., 2006). In this study 
we have shown that the wild type GK promoter was significantly suppressed when cotransfected 
with FoxO1. In addition, when FoxO was cotransfected with HNF-4, the HNF-4α-mediated 
induction of the GK promoter was also brought down by FoxO1. Mutations in the putative FoxO1 
binding site FBEb led to the loss of FoxO1 influenced repression; however, mutation in the FBEa 
did not affect the suppression by FoxO1. Interestingly, mutations in both FBEa and FBEb did not 
abolish the reduction of the HNF-4-induced activity of the GK promoter (Fig 19). However, the 
FoxO1 modulated repression of the GK promoter was lost when the HNF-4 binding element was 
mutated. Since FoxO1 is able to reduce the HNF-4 induction on GK promoter, we expected that 
FoxO1 might physically interact with HNF4 and influence the GK promoter activity. To support 
the idea, we have shown the in vivo interaction of both HNF-4 and FoxO1 by protein pull down 
assays (Fig 23). This clearly explains that FoxO1 interacts with HNF-4α and down regulates the 
GK gene expression in a HNF-4 dependent manner. These data indicate that the FoxO1 effects 
on GK gene expression could be exerted via binding at the FoxO1 binding elements and via 
physical interaction with HNF-4.  
 
5.3.1 Expression of glucokinase during fasting and refeeding 
The hormone insulin will be secreted by β-cells of the pancreas when the blood glucose levels 
are high in order to maintain the glucose homeostasis and further metabolism of glucose. Insulin 
regulates several genes involved in glucose metabolism in a positive and negative manner. 
Mainly the genes involved in glucose catabolism are up-regulated and the genes involved in 
glucose generation are down regulated by insulin via PI3K/PKB. In contrast, glucagon which is 
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secreted by pancreatic α-cells during fasting stages acts antagonistic to insulin. Glucagon is 
known to up-regulate the genes involved in glucose production and reduces the expression of 
genes involved in glucose utilization. Any discrepancies in this balance lead to excess blood 
glucose levels. This severe metabolic malfunction is known as Diabetes. The first step in 
glucose catabolism is phosphorylation of glucose to glucose 6-phosphate which is done by 
glucokinase in the liver. Glucokinase mRNA was induced by several folds when hepatocytes 
were treated with insulin and suppressed by glucagon and cAMP which is a second messenger 
of glucagon signaling (Fig 21 A). In contrast, the expression of the gluconeogenic gene PEPCK 
was enhanced by glucagon and cAMP whereas insulin completely abolished it (Fig 21 A). Many 
investigations on insulin-mediated GK gene regulation suggested that the GK gene is induced 
via PI3K/PKB. However, the molecular details of the GK suppression during fasting were limited. 
When rats were fasted for 48 h the levels of GK protein were completely undetectable, whereas 
48 h fasted rats which were refed for 2 h displayed an induction of the GK protein levels. FoxO 
factors are known to respond to the stimuli of several nutritional and hormonal factors and it was 
shown that fasting and refeeding significantly regulate the gene expression of FoxO factors. 
Imposed fasting for 48 h especially induced FoxO1 to significant levels and refeeding for 3 h 
inhibited the FoxO1 expression to control levels (Imae et al., 2003). Thus regulated FoxO 
transcription factors act on target genes required to maintain the nutritional homeostasis As we 
have observed that GK protein levels were undetectable during 48 h fasting this could be due to 
the effect of up-regulated FoxO1 (Fig 21 B).   
In response to insulin FoxO proteins are known to be phosphorylated by PKB leading to their 
nuclear exclusion. The GK-1448 wild type promoter was induced by 100 nM insulin and 
suppressed by FoxO1 in hepatocytes. The suppression by FoxO1 was completely abolished 
when FoxO1 cotransfected cells were stimulated with 100 nM insulin (Fig 24). During fasting 
stages glucagon activated FoxO1 could suppress the glycolytic genes such as GK and during 
refeeding insulin signaling leads to nuclear exclusion of FoxO1, which in turn would reactivate 
the GK gene transcription.       
 
5.3.2 Effects of resveratrol on glucokinase gene expression 
Resveratrol is an active ingredient of a medicinal plant known as Polygonum capsidatum and it 
has been demonstrated to activate NAD+-dependent SIRT1 deacetylases which activate FoxO 
proteins by deacetylation (Frescas et al., 2005). In this investigation we have shown that GK wild 
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type promoter (GK-1448) activity was reduced when hepatocytes were stimulated with 50 µM 
resveratrol. By contrast, hepatocytes transfected with GK promoter constructs carrying 
mutations in the putative FoxO1 binding sites or the HNF-4 binding site, failed to show the 
FoxO1 effect when stimulated with resveratrol. This data suggest that FoxO1 is activated by 
resveratrol and acts on the GK promoter.   
Resveratrol was shown to possess anti-insulin effects on both glycolytic GK and gluconeogenic 
PEPCK expression. Indeed, the present study shows that increasing concentrations of 
resveratrol down regulate the GK gene expression in a dose dependent manner. Insulin effects 
were almost unchanged when challenged with 10 µM resveratrol, whereas resveratrol at 50 µM 
was able to block the insulin effects and to keep the GK gene expression low while PEPCK 
mRNA levels were reinduced (Fig 25 A). This was also visible at the level of the GK protein.  
To elucidate the repression by FoxO1 and SIRT1 on GK gene expression, hepatocytes were 
transfected with the FoxO1 and SIRT1 expression vectors. FoxO1 suppressed the GK mRNA 
and induced PEPCK mRNA levels significantly. Similar effects were observed on GK and 
PEPCK mRNA levels in the SIRT1 transfected hepatocytes. This explains that FoxO1 might be 
the downstream target of SIRT1 and its transcriptional activity would be induced by 
deacetylation (Fig 26 A).  
 
5.3.3 Deacetylation of FoxO1 by resveratrol 
The FoxO1 protein was shown to be acetylated by the transcriptional coactivator cAMP-
response element-binding protein (CBP) and p300 which leads to the transcriptional attenuation. 
The three major acetylation residues in the FoxO1 include K242, K245 and K262 and are shown 
to be deacetylated by silent information regulator (Sir2) which enhanced the FoxO1-mediated 
transcription (Daitoku et al., 2004). Acetylation of FoxO1 at the three positively charged lysines 
in the FoxO1 DNA-binding domain diminishes the ability to interact with a target gene DNA and it 
promotes the phosphorylation of FoxO1 which excludes FoxO1 from nucleus (Matsuzaki et al., 
2005). Resveratrol was shown to bind SIRT1, the mammalian ortholog of Sir2; causing the 
conformational changes in the enzyme which permit binding to other proteins which are to be 
deacetylated (Borra et al., 2005). In this investigation we have shown that p300 acetylated 
FoxO1 at Lys 242 and Lys 245 whereas resveratrol deacetylated it (Fig 27). This supports our 
previous results showing that down regulation of GK promoter by resveratrol may be due to 
FoxO1 (Fig 22). Based on this, we propose that resveratrol activated SIRT1 deacetylates FoxO1 
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which in turn leads to the repression of GK gene expression. Glucose and pyruvate levels are 
known to fluctuate during fasting, which regulate the ratio between NAD+/NADH. Previous 
investigations identified that increasing concentrations of pyruvate markedly increased the 
SIRT1 protein levels in the liver and these changes in protein levels were shown to be regulated 
at the post-translational levels as SIRT1 mRNA levels were unchanged (Rodgers et al., 2005). In 
addition, this supports that SIRT1 plays a major role in the activation of FoxO1 via NAD+-
dependent deacetylation in response to the nutritional status.  
 
5.3.4 Modulation of glucokinase enzyme activity by resveratrol and FoxO1 
The present study showed that treatment of hepatocytes with insulin induced the glucokinase 
enzyme activity. Increasing concentrations of resveratrol markedly inhibited the glucokinase 
enzyme activity. When hepatocytes stimulated with insulin were challenged with resveratrol, 
resveratrol blocked the insulin-mediated induction of glucokinase enzyme activity. The 
treatments with insulin or resveratrol did not alter the sigmoidal kinetics of the glucokinase 
enzyme and followed Michaelis-Menten curves. Linearization of the Michaelis-Menten curves 
gave Lineweaver-Burk plots which predicted a Km of glucokinase of 10-15 mM (Fig 28 A, B & 
C). Similarly, FoxO1 transfected hepatocytes showed also a reduction in the maximal velocity of 
enzyme activity and did not alter the Michaelis-Menten sigmoidal curves Fig 28 D, E & F). This 
shows that the enzyme by itself appears not to be activated by resveratrol or FoxO1. The 
reduced Vmax of the enzyme is rather due to the low amount of enzyme which was synthesized 
due to inhibition of GK expression by resveratrol and FoxO1. Thus, these enzymatic assays 
strongly support the down regulation of GK mRNA and protein by resveratrol and FoxO1. 
In conclusion, for the first time we have shown that the liver-specific glucokinase gene 
expression is down regulated by FoxO1. During fasting stages the NAD+ / NADH ration will be 
high which will activate the NAD+ -dependent SIRT1 which in turn binds and deacetylates FoxO1 
transcription factors. This leads to the activation of FoxO1 proteins which will be translocated 
into the nucleus and act on its target genes like GK and PEPCK. Thus, in addition to several 
effects of FoxO1 on cell proliferation and apoptosis they are also important for appropriate 
regulation of glucose metabolism.      
 




Figure 30. Regulation of glucokinase and PEPCK gene expression by FoxO1 FoxO1 transcription 
factors are predominantly nuclear and are presumed to be active. Besides acetylation of FoxO1 by a 
transcriptional coactivator p300, insulin via PKB mediates phosphorylation of FoxOs on three conserved 
residues in the nucleus, which initiates their export to the cytoplasm. This would lead to the derepression 
of GK gene expression. Treatment with resveratrol increases NAD+-dependent SIRT1 deacetylases, 
which are known to interact and deacetylate cytoplasmic inactive acetylated FoxO1 into active. Activation 
of FoxO1 by glucagon via cAMP leads to nuclear import and activates the PEPCK gene expression and 
represses the GK gene expression. 
 Insulin receptor substrates (IRS); phosphoinositide 3-kinase (PI3K); protein kinase B (PKB); 
phosphatidylinositol 3,4,5-triphosphate (PI[3,4,5]P3); pyrophosphatase (PPase); cyclic adenosine 
monophosphate (cAMP); Silent information regulator 1 (SIRT1); Glucokinase (GK); Phosphoenolpyruvate 
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